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1. Introduction 
Drug delivery plays an important role in the development of pharmaceutical dosage 
forms for the animal health care industry because often the duration of drug release 
needs to be extended over days up to several months. This can be achieved by 
incorporation of drugs into polymeric materials to control drug release at a predefined 
and reproducible rate for a prolonged period of time. The majority of veterinary drug 
delivery systems are fabricated from non-degradable polymers such as silicone, 
polyurethane and ethylene vinylacetate copolymers, which are inexpensive, 
biocompatible, biological inert and have received regulatory approval [1]. In recent 
years the interest for biodegradable polymers as veterinary drug delivery systems, 
which control and prolong the action of therapeutic agents, has grown in importance. 
The reason being that delivery systems based on biodegradable polymers do not 
require removal from the animals at the end of the treatment period due to their 
degradation into physiologically occurring compounds that can be readily excreted 
from the body. This provides significant benefits such as reduction of animal stress 
resulting from animal handling and physical removal of the delivery system, reduction 
of cost in terms of both finances and time spent by the end-user. 
In veterinary medicine it is important to know whether the drug release system is 
indented for treatment of livestock or for companion animals, which are the two major 
categories of the animal health market. Livestock animals comprise primarily cattle, 
sheep, goats, swine and poultry but also fish and any other animals which enter the 
food chain [2]. 
Livestock industry compares treatment costs with benefits resulting from therapy thus 
the price of the medicament has to be as low as possible to allow profitable 
management for the farmer. On the other hand every visit of a veterinarian is 
associated with costs for the farmer and thus a biodegradable delivery system, which 
requires only a one-time application coupled with increased therapeutic effect, will be 
of economic benefit although the cost of such delivery system may be higher than 
conventional treatment.  
The livestock products dominate the animal health market and account for 
approximately 70 % of total sales. The remaining 30% are attributed to companion 
animal products [3]. Companion animals or pets, such as dogs, cats and horses 
constitute the largest segment. Other animals such as birds, reptiles and rabbits can 
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also be considered as companion animals, however, these species are sometimes 
classified as exotic animals, which represent only a small fraction in the companion 
animal market [4]. The companion animal market is quite different from the livestock 
animal market. For one, the number of animals eligible for treatment is small and the 
outlay is directed toward a single animal. Secondly, companion animals are often 
considered as part of the family and the arbitrary value of the animal for the owner 
allows premium veterinary care. Thus this segment of the animal health market 
presents opportunities for research synergies and spin-offs from human health with 
less consumer safety orietated regulatory pressure than the livestock animal market [5, 
6]. Although human and animal health care industries show many similarities, the 
diversity of species and breeds, the range in body size, regional differences, 
differences in the biotransformation rate and other factors make the development of 
veterinary drug delivery systems more complicated [2]. Furthermore, additional 
regulatory requirements, particularly for food producing animals do exist. Because 
these animals enter the food chain tissue residues must be addressed for both the drug 
and the polymer. Thus residual levels of drug in tissue play an important role as major 
consumer safety issue and are the basis for withdrawal times, which determines the 
earliest time point after administration for slaughter. In the companion animal market 
the owner convenience is responsible for the product acceptance. Although injections 
are common and preferred for livestock animals, oral administration is preferred for 
companion animals. It should be noted, that it is very challenging for the pet-owner to 
administer tablets to the animal, especially to cats, if taste or odor are repulsive to 
them. Thus free choice acceptance of an oral dosage form is important for product 
acceptance. However, in many cases parenteral application is required to achieve 
sufficient therapeutic effect. Thus in companion animal medicine it can also be 
beneficial to formulate a drug, e.g. peptides or proteins into a biodegradable delivery 
system. This would allow to control animal fertility or to treat diseases like cancer in 
an advanced manner, which would improve both patient compliance and owner 
convenience. 
In recent years biodegradable veterinary drug delivery systems such as microspheres, 
implants and in-situ forming implants have been tested in the area of estrus control 
[7], growth promotion [5], control of ectoparasites [8] and vaccine delivery [9].  
Biodegradable polymers, which allow delivery of a range of bioactive materials with 
high bioavailability, have demonstrated their potential for veterinary application. 
3 
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However, presently only few biodegradable drug delivery systems are commercially 
available for veterinary use. Among other reasons, the final price of the device 
followed by regulatory considerations and challenges in formulation stability have 
limited the development of such delivery devices.  
It is the intention of this chapter to give an overview of biodegradable polymers, 
which are used or tested in the veterinary field. The paper will highlight some recent 
developments in this area and will look into the future to examine the directions in 
which veterinary pharmaceutics is heading. Examples of currently available and 
future biodegradable veterinary drug delivery systems will be presented and explained 
including intravaginal devices, injectables and implantable systems. 
2. Biodegradable polymers for veterinary applications 
The most attractive and commonly used biodegradable polymers are polyesters such 
as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) and poly(?-
caprolactone (PCL) (Table 1). These materials are commercially available in different 
compositions and molecular weights which allows control degradation of the polymer 
[10, 11].  
The term degradation designates the process of polymer chain cleavage which leads to 
a loss of molecular weight. Degradation induces the subsequent erosion of the 
material which is defined as mass loss of material ocess of polymer chain cleavage 
[12].  
For degradable polymers two different erosion mechanisms have been proposed: 
homogeneous or bulk erosion, and heterogeneous or surface erosion [13]. The 
difference is illustrated in Fig. 1. Bulk-eroding polymers degrade all over their cross-
section because the penetration of water into the polymer bulk is faster than 
degradation of polymer. In surface-eroding polymers, in contrast, degradation is faster 
than the penetration of water into the bulk. In consequence these polymers erodes 
mainly from its surface. However, for most polymers, erosion has features of both 
mechanisms. The erosion mechanism has consequences for the mechanism of drug 
release which has been classified into diffusion-, swelling- and erosion controlled.  
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Figure 1  Schematic illustration of surface erosion and bulk erosion 
A biodegradable polymer device might release the drug by all three mechanisms and 
the fastest mechanism dominates (Fig. 2). In case of biodegradable polyesters, which 
consist of monomers connected to each other by ester bonds, degradation starts after 
penetration of water into the device. The breakage of ester bonds occurs randomly via 
hydrolytic ester cleavage and leads to the subsequent erosion of the device. The 
hydrolysis rate is influenced by molecular weight, copolymer ratio, polydispersity and 
crystallinity, which can be used to control drug release. For example, poly(?-
caprolactone) which is a high hydrophobic and crystalline polyester degrades very 
slowly compared to amorphous less hydrophobic PLGA. Depending on these 
variables the degradation time varies from several weeks up to years and allows the 
release of drugs over this time period. However, to achieve controlled drug release 
from polyester based delivery systems is difficult because these polymers undergo 
bulk erosion which changes the polymer matrix and influences drug release. As a 
consequence, drug release is controlled by swelling, drug diffusion and polymer 
erosion, which is not straight forward to predict [10, 14, 15].  
The above mentioned polyesters have one characteristic in common: the hydrolytic 
sensitive groups are located in the polymer backbone. This feature stimulated the 
development of a new class of biodegradable polymers based on tartaric acid which 
contain additionally to ester bonds in the backbone, ester as well as ketal bonds in the 
polymer side chains [16] (Table 1). These, so called polytartrates seem to be 
promising due to the modification in the polymer structur. Early experiments 
demonstrated the suitability of described polytartrates for controlled release 
applications [17].  
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Figure 2 Possible mechanism of drug release from degradable polymers  
However, until now these polytartrates have not received commercial status and only 
few information is available about this polymer class [18]. 
Due to the fact that in general polyesters degrade over a longer time period, which is 
disadvantageous when the drug needs to be released for only few days or weeks the 
interest was shifted to polymers, which degrade faster and allow control of drug 
release exclusively by polymer erosion. This leads to the development of poly(ortho 
esters) (POE) and since the late 1970s, four families of POE were developed (Table 
2). The synthesis of POE and their use in controlled drug release has recently been 
reviewed [19]. 
The polymers of the first (POE I) and second (POE II) generation of POE are solid 
materials whereas the polymers of the following generations (POE III, IV) are semi-
solids. They allow the incorporation of therapeutic agents or additives by simple 
mixing, avoiding the need for solvents or elevated temperatures which is a significant 
advantage over other biodegradable polymers. Because ortho ester linkages are acid-
labile, degradation rate can be modulated by pH. Lowering the pH at the polymer-
water interface accelerates the hydrolysis rate whereas an increase of pH results in a 
lower hydrolysis rate [20]. In POE IV the degradation rate of ortho ester bonds is 
controlled by lactic acid units which are generated by cleavage of the polymer 
backbone. The degradation time of POE can vary from few days to several months 
and therefore these polymers are of interest for short- and long acting delivery 
systems [21, 22].  
Another class of biodegradable polymers are polyanhydrides which were investigated 
for drug delivery systems in the early 1980s and their number 
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Table 2 Chemical structures of four families of poly(ortho esters) 
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increased tremendously in the recent years [12, 23]. The best characterized 
polyanhydrides are p(CPP-SA) and p(FA-SA). The first is a copolymer of sebacic 
acid (SA) and 1,3-bis(p-carboxyphenoxy)propane (CPP) whereas the second is a 
copolymer of sebacic and fumaric acid (FA) (Table 1). The advantage of 
polyanhydrides can be seen in the fact that they contain the most reactive functional 
group available for degradation. Based on their chemical nature polyanhydrides 
degrade very fast at a predictable rate for periods of few days up to weeks [23]. Thus 
the main application of this polymer class is in short-term controlled delivery of 
bioactive agents. The degradation rate can be adjusted by hydrophobic and 
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hydrophilic components in the copolymer. In contrast to PLA, PLGA and PCL, 
polyanhydrides and POE are thought to undergo surface erosion since they are 
assembled from fast degrading functional groups. Therefore drug release should be 
controlled mainly by polymer erosion. However it seems that surface erosion is a 
characteristic that is strongly linked to the dimension of a device and that, below a 
critical size limit, this property is lost [24].  
3. Therapeutic applications of biodegradable polymers  
3.1 Biodegradable delivery systems for the control of animal reproduction  
There are two different areas of animal reproduction control: estrus synchronization 
and contraception. Whereas the first is very important for livestock production and 
breeding the latter is of special interest in companion animals.  
In livestock animals deficient estrus detection is in many cases responsible for 
infertility and therefore the major reason for manipulating the estrus cycle. The 
difficulties in estrus detection based among other things on the short period of sexual 
receptivity where ovulation and insemination can take place. Therefore, attempts have 
been made to synchronize estrus to make female animals fertilizable at a 
predetermined time schedule. This has several advantages for the farmer as well as the 
breeder:  
? reduced time and labor currently devoted to estrus detection and to allow more 
cost effective implementation of timed insemination programs 
? increased use of artificial insemination with fresh, transported or frozen semen 
to enhence genetic breeding variability and prevent communicable diseases 
resulting from natural service 
? synchronize donor and recipients for embryo transfer allowing the use of new 
assisted reproductive technologies such as superovulation, in-vitro fertilization 
or cloning 
? allows breeding throughout the year and 
? improving reproductive efficiency and hence farming [2]. 
Poly(?-caprolactone) (PCL) has been shown to be suitable for manufacturing of an 
intravaginal drug delivery system for the delivery of progesterone for estrus cycle 
control and synchronization in cows [25, 26] and sheeps [27]. Cattle were treated for 
7 days either with a PCL insert or the commercially available, non-degradable silicone 
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insert (CIDR-B) both containing 10% w/w progesterone. The PCL insert achieved 
similar average progesterone plasma concentrations compared to the silicone insert 
over the 7 days insertion period [25].  
The incorporation of excipients such as lactose, polyethylene oxide or various types of 
cyclodextrin can be used to modify progesterone release from the intravaginal insert 
[26]. Anestrus sheeps, which were treated with a progesterone-containing PCL insert, 
showed elevated plasma progesterone levels similar to those obtained from the 
commercial silicone insert (CIDR-G) over the 14 days insertion period [27].  
Recently, a more versatile PCL intravaginal insert was developed which allows the 
incorporation of a large number of drugs [28]. This was achieved by using both 
extrusion and injection molding technique. Progesterone and PCL were compounded 
by extrusion to small pellets which were then injection molded into inserts. 
Additionally, the surface area of the insert was modified by cutting off certain 
sections of formed insert and replacing with blank PCL. Ovariectomized cows were 
administered either the optimized PCL insert or a commercial silicone insert (CIDR-
B). To achieve the same plasma progesterone levels as the CIDR insert the surface 
area of the PCL insert was increased. It was found that the surface area is the only 
significant variable, which effects plasma progesterone concentration. The 
pharmacokinetic values over a 7-day insertion period suggest that the optimized PCL 
insert is bioequivalent to the commercial silicon insert. The PCL insert was well 
tolerated by the animals and field studies have shown that the PCL insert containing 
10 % w/w progesterone to be clinically at least as effective as the commercial product. 
In addition to intravaginal inserts biodegradable microspheres were investigated to 
control estrus and ovulation in horses [29, 30], pigs [31], and cattle [32].  
In general, poly(D,L-lactide) has been used to produce steroid containing 
microspheres by a solvent extraction process and currently one formulation is 
commercial available for accurate control of ovulation in mares (Lutamate Plus).  
The microspheres for intramuscular injection (i.m.) contain 100 mg estradiol and 1250 
mg progesterone. In a controlled multicentered clinical trial using 135 mares the 
proportion of mares displaying a normal estrus following treatment increased from 63 
to 87%. The variation for days in estrus decreased which demonstrated the clinical 
efficacy of this product [29]. In a separate study DL-PLA microspheres containing 
100 mg estradiol were also successfully tested in horses [30]. The administration of 
this formulation to pigs resulted in pseudopregnancy for greater than 50 days. This 
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was successfully used to induce estrus on day 59 by application of a commercial 
PGF2? product [31]. For estrus control in cattle a combination of two different 
progesterone containing DL-PLA microspheres was investigated. The observed 
plasma progesterone levels were similar to those observed following intravaginal 
administration of a commercial available progesterone insert [32].  
To achieve fertility control in pets various biodegradable delivery systems were 
investigated for the application of gonadotropin-releasing hormone (GnRH) analogs. 
PLGA is the most frequently studied polymer in this field and microparticles [33], 
extruded implants [34, 35] or in-situ formed implants [36, 37] prepared from various 
types of these polymers containing GnRH analogs were successfully used for 
chemical castration in dogs for 1 to 6 month. 
Other polymers that were investigated for reproduction control in veterinary field are 
polyanhydrides. To induce ovulation and spermiation in fish p(FAD-SA) 
microspheres containing a gonadotropin-releasing hormone (GnRH) analog (D-Ala6, 
Pro9NEt-GnRH) were prepared by a double emulsion technique [38]. Two 
commercial important fishes, the striped bass and the Atlantic salmon were treated. 
All female fishes ovulate either within 11 days (Stripted bass) or 15 days (Atlantic 
salmon) after microsphere administration and were also effective in enhancing sperm 
production in male fishes.  
However, scaling up commercial microspheres production to meet the demands of 
animal market is a very complex process which required costly facilities, water 
systems and equipment [5].  
A more cost effective delivery system compared to microspheres are implants formed 
in-situ. The technology based on the fact that biodegradable polymers like PLGA 
spontaneously form solid depots when a solution of the polymer is injected into water. 
First, the polymer is dissolved in a pharmaceutically acceptable solvent such as N-
methyl-2-pyrrolidone (NMP) or benzoyl benzoate. Thereafter the solution is mixed 
with the active pharmaceutical ingredient and the resulting solution or suspension can 
be easily injected either subcutaneously or intramuscularly using a small gauge needle 
[7, 39].  
After injection displacement of the carrier with water in the tissue fluids causes the 
polymer to precipitate to form a solid film or implant (Atrigel technology). The 
drug encapsulated within the implant is then released in a controlled manner as the 
polymer matrix biodegrades with time. The timeframe of the release can be adjusted 
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using different formulation variables, chiefly by altering the polymer composition and 
molecular weight [40]. The Atrigel technology was recently investigated for the 
controlled release of leuprolide in rats and dogs [36, 37]. Serum testosterone and 
leuprolide levels showed no significant difference in the pharmacologic efficacy 
compared to marketed leuprolide-containing microspheres (Lupron Depot). Due to 
the simple manufacturing technique this technology is more cost effective than 
marketed microspheres and implant products and appears promising for product 
development. However, NMP which is often used as solvent for PLGA causes pain 
reactions during the application and therefore alternative solvents would be beneficial 
for veterinary use [7]. 
Viscous poly(ortho esters) allow subcutaneous injection and avoid the need for 
organic solvents. Recently, a low molecular weight POE, containing 30 % of lactic 
acid units in the polymer backbone (POE70LA30) was used for estrus 
synchronization in sheep [41]. Fluorogestone acetate (FGA), a potent synthetic 
progestagen, which is used in several non-degradable intravaginal inserts or sponges, 
was added to POE70LA30 (1.5 and 3 % w/w) by mixing. The addition of 20 % 
poly(ethylene glycol) increased the syringeability of the formulation and  the 
cumulative release. Nevertheless, FGA was released slowly and almost constantly and 
only 29 % of incorporated FGA was released in vitro after 14 days. In vivo testing in 
sheep is currently in progress to determine the efficacy of these POE-based 
formulation.  
3.2 Biodegradable delivery systems for the control of ectoparasites 
The control of ectoparasites such as fleas, flies, ticks and mites is of great importance 
in the animal health market. In livestock animals infections with ectoparasites leads to 
animal suffering and hence to e.g. weight loss and reduced milk production which 
effects finally the productivity. In companion animals ectoparasites causes e.g. skin 
diseases which affect the well-being of the animals. The research and development 
costs for the discovery of new chemical entities to control parasites in both lifestock 
and companion animals have increased significantly. In parallel advances have been 
made in the development of biodegradable drug delivery systems [42]. For such 
delivery systems drug substances which are highly efficient at extremely low dosages 
are ideal candidates such as ivermectin, a semi-synthetic macrocyclic lactone [43].  
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Ivermectin containing microspheres were obtained by a solvent evaporation technique 
using PLGA, copolymer ratio 50:50 and 90:10, as well as PLA as matrix [44]. The 
three formulations were tested in Spanish goats and ivermectin was released at 
therapeutic levels about 10-12 weeks from PLGA microspheres or in combination 
with PLA microspheres released for at least 24 weeks. The PLGA 50:50 formulation 
controlled the ticks for 12 weeks after treatment. In addition, the treatment provided 
inhibition of larval horn flies in the manure of treated animals for 10 weeks.  
The efficacy of injectable microspheres containing 30 % ivermectin for control of 
cattle fever ticks was tested using a blend of PLGA microspheres (half 50:50 
copolymer and half 65:35 copolymer) [45]. No engorged ticks were found 4 weeks 
after treatment until the end of the study at week 16. The treatment eliminated also the 
tick population in the pasture where the cattle were held. In addition, treated cattle 
gained an average of 35 kg more than untreated animals [46]. 
The application of PLGA and PLA yielded to a long-term delivery system for 
ivermectin, which needs to be administered less frequently than commercial bolus 
systems (IVOMEC® SR). Furthermore, the total quantity of drug needed to control 
ectoparasites is reduced when using microparticles instead of an intraruminal bolus 
system.  
Recently a product based on a biodegradable polymer for the prevention of canine 
heartworm in dogs was approved and is available in Australia, the USA (ProHeart) 
[47] and Italy (Guardian SR Injectabile) [48].  
Moxidectin, an ivermectin derivative was incorporated into PLGA microspheres and 
protection against heartworm infection was achieved over a period of 6 months [49, 
50] up to 1 year [48].  
Poly(D,L-lactide) and PLGA were also tested for control of cattle grubs using 
methoprene, a juvenile hormone mimic, which was formulated into implantable 
pellets or microspheres [51]. When injected subcutaneously in the ears of infested 
cattle the formulations prevented the emergence of adult cattle grubs. 
Polycaprolactone was also investigated as release agent for methoprene and insect 
steroid analogues against ticks [52, 53].  
Another polymer that has been tested for control of ectoparasites is POE. Ivermectin 
was covalent bonded to the POE monomers during synthesis and the resulting 
crosslinked polymer mass was finally extruded to a rod. The rod, which was indicated 
for control of heartworm in dogs, released ivermectin for as long as 6 months [54]. 
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3.3 Biodegradable delivery systems for vaccination 
Prevention of infectious diseases is a primary concern of animal health. Infectious 
diseases cause economic losses for livestock producers due to the decreased 
productivity. On the other side, without a good vaccination program, companion 
animals would suffer many serious infections. To prevent loss of animals vaccination 
is the most successful procedure.  
A good vaccine delivery system is characterized by a controlled release of antigen in a 
pulsatile manner over a long time period to eliminate or reduce the need of subsequent 
inoculation and achieves a very effective protection against the intended disease. 
Biodegradable microspheres have been widely investigated for vaccine delivery [55, 
56, 57, 58]. In literature are also many reports documenting the great potential of 
biodegradable polymers for the prophylactic control of veterinary pathogens but until 
now there are no commercially available veterinary vaccines. Some examples for 
vaccine delivery using biodegradable polymers that have been evaluated in veterinary 
medicine are given in Table 3. 
Copolymers of polylactide and polyglycolide esters have been widely used to 
produce biodegradable microspheres that act as depot for vaccine antigens [59, 60]. 
Microspheres less than 10 µm in diameter have been reported to be phagocytosed by 
macrophages whereas larger particles have to breakdown in vivo before they can be 
phagocytosed. This was demonstrated by injecting mice intraperitoneally 
staphylococcal enterotoxin B toxoid containing PLGA microspheres of 1-10µm and 
20-125µm in diameter or a mixture of both [59]. Thus administration of a 
microspheres mixture, which differs in particle size, can induce long lasting 
immunity. This can also be achieved by using microparticles of different composition 
and molecular weight. The concentration of antigen affects also the rate of antigen 
release and subsequent induction of immune response. The higher the 
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Table 3  Biodegradable delivery systems for vaccination 
 
Delivery system 
Polymer 
Microspheres In-situ implant 
Virus/ Bacteria 
Target 
animal 
PLGA [59]  Staphylococcus  
  [60] Ovalbumin antigen 
Mice, 
swine 
  [60] 
Inactivated Pseudoarabies 
virus (PRV) 
Swine 
  [60] Parvovirus Canine 
 [61]  
Venezuelan equine 
encephalities (VEE) virus 
Horse 
 [62]  Parainfluenza-3 virus Cattle 
 [63]  Salmonella enteritidis Poultry 
 [64]  Fascioloa gigantica Cattle 
 [66]  Rabies virus  
 [67]  Salmonella thyphimurium  
 [68, 69]  Tetanus toxoid  
 
antigen loading the faster the release due to the presence of more antigen near the 
surface [60]. 
There are many viral infections of animals that require vaccines to induce antibodies. 
However, in many cases cell mediated immunity is necessary or beneficial to prevent 
diseases. Inactivated Venezuelan encephalitis virus (VEE) has been encapsulated in 
PLGA microspheres was injected to mice. Mice, which were vaccinated with 
microspheres, were better protected than mice treated with unencapsulated virus. Such 
a vaccine may be useful to prevent encephalitis for e.g. horses [61]. An example for 
encapsulation of a viral vaccine into PLGA microspheres is the parainfluenza-3 virus. 
This virus is part of the respiratory disease complex that causes high economic losses 
in beef cattle in North America. Cattle, which were treated with PLGA microspheres 
containing parainfluenza-3 virus, showed high antibody titers for up to 70 days [62]. 
In another veterinary example  
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PLGA was encapsulated with Salmonella enteritidis, a bacterial vaccine [63]. The 
microspheres were administered to hens for preventing infection in chickens by 
passive immunity in the yolk. The tested formulation was effective in stimulating the 
immune system for 9 month. 
The encapsulation of Fasciola gigantica subunit antigen into PLGA microspheres 
demonstrated the feasibility of PLGA microspheres for delivering subunit antigens 
from intestinal/ systemic parasites of veterinary importance [64]. Fasciola hepatica is 
a worm that damages the liver and causes the disease liver fluke. The disease 
primarily affects cattle and sheep but also horses; deer, goats, pigs and dogs. This 
disease costs farmers over US$ 25 Million, yearly [65] with deaths and lost 
production, due to reduced weight gains, milk production and fertility. These very 
serious losses could be greatly reduced by the treatment of animals with a suitable 
vaccine formulation.  
As described previously, PLGA and their homopolymers are suitable polymers for the 
in-situ implant technology. In a pilot experiment the Atrigel formulation, 
containing ovalbumin (OVA) as antigen was tested in mice and swine. It could be 
shown, that the in-situ implant effectively immunized swine to produce IgG response 
against small amounts of enclosed OVA after a single administration. Subsequent 
experiments demonstrated that the Atrigel technology is also suitable for delivering 
of complex antigens such as inactivated pseudorabies virus (PRV) vaccines to swine 
[60]. 
3.4 Biodegradable delivery systems for growth promotion 
Growth promoting implants using steroids have been used for over 40 years in 
livestock production because they improve growth rate (+10 to 30%), feed efficiency 
(+5 to 15%) and carcass leanness (+5 to 8%) [70].  
A continuing goal of livestock industry is to increase the quantity of high-quality lean 
tissue. The development of recombinant technology allowed the large-scale 
production of somatotropin and their commercial use to increases lean content and to 
reduce fat content of meat. Somatotropin increases also the milk production in dairy 
cows. However, somatotropin as well as other peptides and proteins loose on activity 
when dosed orally and the absorption via this route is poor due to their 
physicochemical properties [71]. Thus parenteral delivery systems for sustained 
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release of growth promoting peptides and/or proteins such as somatotropin, growth 
hormone releasing factor (GHRF) analogs or synthetic growth hormone releasing 
hormones (GHRH) are continuously under development in veterinary medicine.  
Biodegradable polymers, especially in the form of injectable microspheres have been 
investigated for their capability of releasing growth promoting drug substances to 
livestock animals [71, 72, 73, 74]. Polyglycolic acid was used to encapsulate porcine 
somatotropin (pST) into microspheres. However, an incomplete release (less than 
30% of drug loading) was observed, which was assigned to the instability of pST 
within this formulation [73]. This resulted in the development of more stable peptides 
and proteins, which stimulate the release of somatotropin, such as GHRF analogs and 
rismorelin porcine, a synthetic GHRH. Poly(lactide-co-glycolide), copolymer ratio 
85:15, and rismorelin porcine were formulated into microspheres using a modified 
solvent evaporation process, which reduces the water solubility of the peptide and 
decreased loss of peptide during process [74]. Administration of rismorelin porcine-
containing microspheres to pigs leaded to reduce excretion of urea nitrogen in urine 
and serum, which indicated that pigs converted urea into protein and muscle as 
response of treatment. Rismorelin porcine was delivered at a consistent rate over an 
extended period of time, which demonstrated that PLGA microspheres are suitable for 
long term delivery of this peptide. It should be noted that the duration of activity 
depends among other things on the suspension vehicle, which is used for 
microspheres injection. Another approach to enhance growth performance was the 
administration of PLGA microspheres containing a GHRF analogue to cattle [72]. 
Released GHRF analogue caused an increase in serum somatotropin concentration 
over 2 weeks and future studies are necessary to determine which serum ST 
concentration is sufficient for growth promoting.  
Currently there is no biodegradable formulation for growth promotion on the market. 
A reason therefore is the high cost which is necessary to insure product quality and 
consistency. A delivery device based on PLGA for the long-term delivery of 
monensin sodium, an antimicrobial agent to promote growth promotion in cattle, is no 
longer commercial available (Monensin RDD)[75]  
The use of growth promoting agents such as hormones and antimicrobial agents in 
food producing animals is critically assessed in the European Union (EU) and 
controlled by regulations from the European Commission.  
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3.5 Further application of biodegradable polymers in animal health 
The various classes of biodegradable polymers, which differ more or less in their 
physicochemical properties and degradation behaviour offer the possibility to 
formulate a range of drugs into a biodegradable delivery system. Indeed only few 
biodegradable delivery systems, e.g. antiinfectiva [76, 77, 78, 79], vitamin nutritionals 
[80], antiemetica [81] and cytostatica [82], are described in literature for animals.  
Poly(D,L-lactide) microspheres loaded with either ofloxacin or clarithromycin, both 
macrolides, are examples for the potential of biodegradable polymers to release 
antibiotic drugs in an advanced manner to animals [76, 77]. Recently, a novel 
biodegradable injectable gel formulation for the prolonged release of oxytetracycline 
(OTC) was investigated in sheep [78]. The gel was obtained by adding a great amount 
of plasticizers to a mixture of different molecular weight PLGAs in which OTC (20 
% w/w) was dispersed. The plasma concentration of OTC at or above the minimum 
inhibitory concentration (MIC) was observed for a period of 6 days. However, only 69 
% of OTC loading was released after 15 days and further formulation development 
will be necessary to achieve complete release and to decrease reaction on injection 
site. 
Currently the Atrigel technology was successfully used to develop a dental gel for 
the treatment of periodontal disease in dogs. The antibioticum doxycycline, a 
tetracycline derivate, is released from the DL-PLA implant which is formed in situ for 
at least 7 days (HESKA PERIOceutic Gel) [83]. 
Another example for biodegradable antibiotics are PLGA microspheres containing 
cephradin, a ß-lactam antibiotic which was developed for cattle. Preliminary 
investigations using dogs showed that therapeutic plasma levels of cephradin were 
obtained for up to 48 h, although cephradin has a short half-life time of 71 min [79].  
Poly(lactide-co-glycolide) was also used for the preparation of a controlled release 
formulation of a vitamin. Microparticles loaded with Vitamin B12 can be used to 
improve energy and protein metabolism in animals. A formulation has achieved 
commercial status and is launched in New Zealand (SmartShot) [80]. The 
formulation releases continuously the vitamin for a period over more than 20 days. 
Other interesting polymers for veterinary application are injectable semi-solid 
poly(ortho ester). A paper has recently reviewed their potential in human as well as 
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animal health [22] and one possible application for companion animals is the 
treatment of gastrointestinal disorder (GD) in dogs.  
Metoclopramide is a useful agent in treating and preventing various types of vomiting, 
which is one characteristic of GD. Due to the short biological half-life it is usually 
administered up to four times daily orally in order to maintain therapeutic 
concentration over the hole day [81]. To prevent fluctuation of plasma level, which 
produces adverse reactions especially in long-term therapy as well as to improve the 
compliance, a retard formulation for 3-5 days would be beneficial. This was achieved 
using a viscous POE to which the drug was added by simply mixing. Preliminary 
pharmacokinetic results in dogs showed sustained plasma concentration for up to 30 
hours. Further development is necessary to prolong the period of drug release.  
4. Conclusion and perspectives of biodegradable polymers for veterinary 
application 
Biodegradable polymers have proven their potential use for the development of new, 
advanced and efficient drug delivery systems. Those are capable of delivering a broad 
range of bioactive materials in a broad range of veterinary applications.  
Suitable therapeutic agents for such biodegradable drug delivery systems are 
generally those that need to be administered over a long period of time, which are 
highly active or have a short biological half life such as peptides and proteins. 
In the last two decades technological advances have made the production of 
biodegradable delivery systems more practical and economical. However, until now 
only few biodegradable delivery systems have entered the market on both human and 
veterinary side. 
The reasons are obvious: At first many drugs such as peptides and proteins are 
sensitive to heat, shear forces or organic solvents. But those are required for most of 
the manufacturing processes of classical biodegradable delivery systems such as 
microspheres or implants. Thus solvent free and sparing methods are of significant 
interest to avoid stability problems during manufacturing. Furthermore polymers 
which allow the incorporation of sensitive and/ or instable drugs by simple mixing, 
without using heat or solvents such as viscous poly(ortho esters) are promising.  
Secondly, several factors such as moisture, acidification or interactions between 
polymer and drug leads to stability problems during storage and release. Last but not 
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least the often desired zero-order release profile cannot be achieved due to the 
combination of diffusion and erosion processes. In consequence, the drug release rate 
varies over the time, especially in the case of long-term applications. Thus, a 
prediction of the in vivo release based on in vitro data is very difficult and a matter of 
concern due to the time and cost intensive experiments necessary to development 
suitable in vitro test systems.  
The most important step to overcome this problem is to fully understand the 
degradation mechanism of applied polymer in order to allow adjusting of release 
profile. Although systematic degradation studies have been performed especially with 
aliphatic polyesters the degradation mechanism of these polymers is still not 
completely understood and demands further investigations.  
Nevertheless, in the future many new therapeutic agents will require parenteral 
application and might benefit from the advantages of biodegradable polymers. 
Currently promising biodegradable applications are under investigations for 
veterinary applications such as guided tissue regeneration, ocular diseases, single-shot 
vaccination, osteoarthritis or fertility control.  
 
Aims of this Thesis 
The research described in this thesis was aimed to investigate a series of low 
molecular weight poly(D,L-lactides) in order to obtain information about their role in 
the degradation process of aliphatic polyester which is a controversial subject in 
literature. Since the solubility of these oligomers is discussed as critical factor in the 
current theory of bulk erosion and mechanistic degradation studies depending on this 
issue have not been reported yet it was one aim of this thesis to address this task. 
Another aim of this thesis was to investigate the degradation and release 
characteristics of a branched tartaric acid based polyester, poly(2,3-(1,4-diethyl-co-
2,3-isopropyliden)tartrate) (PTA) with respect to its potential use for veterinary drug 
delivery systems.  
A third aim of the thesis was to investigate the possibility to develop different levels 
of in vitro-in vivo correlation (IVIVC) by using model-dependent and model-
independent methods. Due to the fact that drug release from biodegradable delivery 
  Chapter 1 
21 
systems occurs by different release mechanisms such as diffusion, dissolution and 
erosion, IVIVC is still a major problem and a great challenge. 
Organization of this thesis 
In order to investigate the degradation mechanism and degradation kinetics of low 
molecular weight poly(D,L-lactides) as function of chain length in Chapter 2 the 
synthesis and characterization of a homologous series of low molecular weight 
poly(D,L-lactides) is described. According to Shih, base-catalyzed hydrolysis should 
proceed by random scission mechanism, whereas in acid catalyzed hydrolysis chain 
end scission should be predominant. Since degradation causes an increase in the 
number of carboxylic acid groups which are thought to auto-catalyze ester hydrolysis, 
degradation rate should be faster at low pH values.  
Chapter 3 reports the incorporation of oligomers into PLGA films in various 
concentrations by a solvent casting method. The aim of this chapter is to verify the 
autocatalytic effect of oligomers on the degradation of polymers as reported in 
literature. Furthermore, the interest is focused on morphological changes during 
degradation, which could be caused by oligomers. 
In Chapter 4 a less known polyester based on tartaric acid, PTA is characterized in 
order to investigate the degradation mechanism, which has not reported yet. The 
polymer contains in contrast to PLGA or PLA additional ester as well as ketal groups 
in the polymer side chain. It is expected that due to this chemical structure the 
hydrophobicity of the polymer is increased and thus degradation should be delayed 
compared to PLGA. In a set of experiments the degradation behavior of PTA implants 
is monitored regarding to the bulk erosion concept and the morphology of the 
degrading implants. 
In Chapter 5 the interest is focused on the evaluation of drug release from PTA 
implants with respect to the potential use of this polymer for veterinary applications. 
The influence of PTA degradation and erosion is investigated with respect to drug 
loading, implant size and incorporation of excipients. According to Bengs a small 
initial drug release is expected which is followed by phase of rather constant drug 
release.  
Chapter 6 reports the preliminary results of the development of a biodegradable 
implant for veterinary use. The aim of this chapter is to assess the in vitro release 
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mechanism of buserelin implants which differ in drug loading, coating and copolymer 
ratio and finally to determine the pharmacokinetic parameters of three selected 
formulations in dogs. By using different methods such as statistical moment analysis 
and deconvolution an attempt will be made to develop different levels of correlation.  
In the last chapter, the Conclusion, the results of this thesis are summarized and some 
suggestions for future research are presented. 
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Abstract 
A series of low molecular weight polymers of D,L-lactic acid has been synthesized. 
The oligomers were characterized with respect to molecular weight, glass transition 
temperature and solubility. The number average molecular weight of the oligomers 
ranged from 290 to 1320 Da. Oligomers with an nM < 800 Da were soluble in buffer 
at pH 7.4 but insoluble in water and acidic medium.  
Kinetic studies were performed at pH 1.5, 4.5 and 7.4 using an accelerated in vitro 
monomer release test. The average hydrolytic rate was dependent on molecular 
weight of oligomer, temperature and pH of the media, with the lowest rate found 
around pH 4.5. The activation energy was dependent on molecular weight and ranged 
from 47 to 67 kJ mol
-1
. 
Chain-end cleavage (unzipping) was identified as mechanism of hydrolysis in 
acidic media whereas random ester and/or backbiting at the chain ends were the 
possible mechanism of hydrolysis in basic media. 
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1. Introduction 
Poly(lactic acid) (PLA) and its copolymers with poly(glycolic acid) (PGA) are widely 
used for pharmaceutical and biomedical applications because they are biodegradable 
and biocompatible [1]. An important attribute of these polymers is the possibility to 
modulate the degradation rate of a delivery system by changing e.g. chemical 
composition (homo- or copolymers of lactic and glycolic acid) or the physical 
properties (molecular weight, glass-transition temperature) and consequently to 
control the drug release [2]. Therefore, the degradation mechanism of polyesters has 
been a subject in numerous investigations [3-7]. The results of these studies are 
somewhat controversial and until now the role of low molecular weight degradation 
products (oligomers) in the degradation process is not fully understood. Generally the 
hydrolytic degradation of polyesters in aqueous media proceeds through random ester 
bond cleavage in the bulk of the device [4, 8, 9]. This process is affected by four 
principal parameters, namely rate constant, amount of absorbed water, diffusion 
coefficient of chain fragments within the polymer matrix and solubility of degradation 
products in the surrounding medium.  
The most common explanation for this heterogeneous degradation process is as 
follows [10-12]: degradation starts with the absorption of water, followed by the 
hydrolytic cleavage of ester bonds, which generates chain fragments with acidic end 
groups. This process is characterized by a decrease in molecular weight, an increase in 
the polydispersity P (= Mw/ Mn) and a lack of polymer mass loss. In the initial 
degradation phase the cleavage of ester bonds occurs preferentially at the surface of 
the device due to the gradient of absorbed water. After a short period of time this 
gradient disappears, because water diffusion is relatively rapid in comparison to 
polymer-chain degradation. The discovery of a faster degradation inside larger 
devices greatly changed the understanding of polymer degradation. The 
heterogeneous degradation was assigned to reaction/diffusion phenomena which 
were identified to govern polymer degradation [12, 13]. These phenomena involve 
water soluble, low molecular weight degradation products, which are formed at the 
surface as well as in the inner part of the device. In contrast to small size devices 
where soluble oligomers can escape before they are totally degraded, in large size 
devices only soluble oligomers located close to the surface are extracted whereas 
those located inside the device remain entrapped due to the relatively small diffusion 
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coefficients of oligomers. In consequence the concentration of carboxylic end groups 
is higher in the center than at the surface and thus increasing the degradation rate. 
Therefore, it has been suggested that the degradation of large devices leads to a 
surface-center differentiation due to the phenomena described above, also designated 
as autocatalysis. It is also known that ions from the medium decrease the relative 
acidity of the surface and form an acidity gradient from surface to center, which 
contributes to such differentiation [12, 14]. 
It was also postulated that oligomers produced during the hydrolysis create an osmotic 
pressure between the interior of the device and the surrounding medium, which can be 
explained as well by the reaction/ diffusion phenomenon [15]. This osmotic 
pressure draws water into the matrix and the outer layer acts as semipermeable 
membrane. All effects lead to a faster degradation in the center than at the surface. It 
is assumed that if internal degradation products become small enough to be soluble 
(critical molecular weight of oligomer) and the surface becomes permeable they can 
escape, in parallel mass loss is detected. With increasing polymer chain length more 
bonds have to be cleaved in order to generate water-soluble oligomers, therefore time 
until onset of mass loss increases.  
Whether bulk or surface erosion occurs depends on the formation velocity of diffusing 
oligomers [16]. Recently it has been reported that depending on device geometry 
degradation can shift from bulk to surface erosion [17]. 
In the literature only scant information is available on the critical molecular weight for 
water solubility of oligomers and their degradation behaviour [18-20]. The numbers 
range from 1500 Da up to 5000 Da [21-23]. Furthermore, only few reports dealing 
with the effect of oligomers with various molecular weights on the degradation profile 
of polymer devices have been published [20, 24, 25]. 
The objective of this paper was to synthesized a series of oligo-D,L-lactides with 
narrow molecular weight distribution and to characterize them with respect to their 
physico-chemical properties as function of average chain length. To obtain 
information about the degradation kinetics of oligomers the degradation was 
monitored using either an accelerated monomer release test based on high 
performance liquid chromatography (HPLC) or nuclear magnetic resonance 
spectroscopy (NMR). The paper gives new information about oligomer properties 
which should be helpful to understand degradation of polymers.  
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2. Materials and methods 
2.1 Materials 
90 % D,L-lactic acid (LA) in aqueous solution was obtained from Sigma (Germany). 
Tetrahydrofuran (THF) in spectroscopic grade, dichloromethane (DCM) and ethanol 
were purchased from SDS (Germany). Deuterated acetone (aceton-d6), deuterium 
oxide (D2O), deuterochloric acid (DCl, 20 % in D2O), acetonitrile-d3 (ACN-d3), 4-
N,N-dimethyl- 
aminopyridine (DMP), phenolphthalein, trifluoroacetic acid (TFA), petroleum ether 
and 0.1 N sodium methylat solution (NaOCH3) were obtained from Merck 
(Germany). All materials used were of analytical purity. 
2.2 Synthesis of D,L-lactic acid oligomers 
Polydisperse lactic acid oligomers with varying average molecular weights were 
synthesized according to [26]. 100 ml of 90 % D,L-lactic acid aqueous solution was 
allowed to concentrate by gentle distillation of water. The reaction started at normal 
pressure and was then changed to reduced pressure after removal of water. The 
temperature was slowly increased to reach 140 °C after 3 days. At various time points 
of polymerization a sample was taken and analyzed for number average molecular 
weight ( nM ). The synthesis times ranged between 4 hours and 8 days. The yield of 
oligomer production ranged between 56 and 83 %. All samples were stored in a 
desiccator at room temperature. 
2.3 Characterization of oligomers 
2.3.1 End group analysis 
The quantity of carboxylic group in each oligomer was determined by titration of the 
oligomer solution with 0.1 N NaOCH3. Each sample was dissolved in DCM and 
diluted with ethanol (2 % w/ v). Phenolphthalein was added and the solution was 
titrated with 0.1 N NaOCH3. The volume of alkali solution consumed for titration was 
used to calculate the number average molecular weight of the oligomer by using Eq. 
(1) [27]:  
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where W is the weight of the oligomer titrated. C is the concentration of the NaOCH3 
solution. V and V0 are the volume of the NaOCH3 solution used for titration of 
oligomer solution and blank, respectively. Results are the mean of 5 determinations. 
2.3.2 Size exclusion chromatography 
The molecular weights and molecular weight distributions of polydisperse D,L-lactic 
acid oligomers were determined by SEC using styragel columns (PSS guard column 
SDV, PSS SDV 100, 5 µm, 300 x 7.5 mm, Polymer Standard Service, Mainz, 
Germany)[28]. Degassed THF containing 0.1 % (v/ v) trifluoroacetic acid (TFA) was 
used as the mobile phase at a flow rate of 1 ml/ min. An oligomer aliquot was 
dissolved in THF and filtrated before injection. The average molecular weight was 
determined relative to polystyrene standards (Polymer Standard Service, Mainz, 
Germany) using refractive index detection at 30 °C.  
2.3.3 NMR spectroscopy 
For 
1
H-NMR spectroscopy a polar solvent was used for the dissolution of oligomers 
as recommend by Espartero et. al [7]. Samples were dissolved in acetone-d6 (1 mg/ 
ml) and the spectra were recorded on a Jeol spectrometer operating at 500 MHz at 
room temperature (16 scans). 
Chemical shifts (?) were expressed in ppm with the acetone-d6 signal at 2.06 ppm as a 
reference. The average degree of polymerization ( nDP ), nM  and the monomer 
content were determined from the ratio of integrals of different ?-methyl proton 
signals (? 1.2-1.5 ppm) described in [7]. 
2.3.4 Differential scanning calorimetry  
Measurements of glass transition temperatures (Tg) were performed using a 
differential scanning calorimeter (DSC 821, Mettler Toledo, Greifensee, CH). Two 
samples (approx. 7 mg) of each oligomer were heated twice under nitrogen 
atmosphere. Thermograms covering a range of -60 °C to 200 °C were recorded at 
heating and cooling rate of 10 K/ min. The second DSC scan run was used for Tg 
34 
  Chapter 2 
 
calculation (onset method). Calibration of the system was performed using gallium 
and indium standards.  
2.4 In vitro degradation 
From an analytical viewpoint several techniques such as SEC, HPLC, capillary zone 
electrophoresis or mass spectrometry can be used for monitoring degradation in vitro 
[29-32].  
In this work degradation was measured by the appearance of lactic acid in the release 
medium using HPLC. It should be note, that the applied test could be used in 
combination with e.g. mass spectroscopy for more quantitative determination of 
degradation profiles. 
The monomer release studies were carried out in buffer solutions at pH 1.5, 4.5 and 
7.4. 50 mg of each oligomer (n=5) were placed in an iodine flask containing 25 ml of 
selected medium and incubated at 65 °C. The activation energies were determined by 
conducting studies at pH 7.4 at 70, 80 and 90 °C. 
At defined time intervals 2 ml of medium were withdrawn and replaced by fresh 
medium. Samples were frozen until the study was completed and analyzed for lactic 
acid content by HPLC according to the procedure described in [33]. The following 
modifications were applied. Separation was performed on a C 18 column (250 x 4.6 
mm I.D., Machery Nagel, Düren, Germany) fitted with a guard column. The mobile 
phase, phosphate buffer (pH 2.9) was used with a flow gradient. The UV-VIS detector 
(Waters 2470, Waters Corporation, Milford, MA) was set at 210 nm. The column 
temperature was maintained at 35 °C using a column oven (Jet Stream, Waters 
Corporation, Milford, MA). All samples were stored at 6 °C in the autosampler.  
Calibration curves were generated from known concentrations of D,L-lactic acid in 
buffered media. The detection limit was 5 µg/ml. 
2.5 Hydrolysis mechanism 
In accordance with previous experiments performed by the group of Shih et al. [34, 
35] the hydrolysis mechanism was investigated using either DCL or DMP as catalyst. 
Each oligomer sample (approx. 20 mg) was dissolved in ACN-d3 (approx. 1.5 ml) in a 
volumetric flask (2 ml). Then 0.2 ml of DCl (1.18 M in D2O) or 0.5 ml of DMP 
(0.933 M in D2O) was added, respectively. The flask was finally filled with ACN-d3.  
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The concentration of DCl and DPM in the reaction mixture was 0.118 M and 0.223 
M, respectively. An aliquot (approx. 0.8 ml) of the solution was immediately 
transferred to a NMR tube and sealed. Spectra were taken as described above over a 
24 h period at room temperature. Chemical shifts were expressed in ppm referencing 
to the ACN-d3 signal at 1.96 ppm. 
3. Results and discussion 
3.1 Characterization 
A series of oligo(D,L-lactic acids) were synthesized by direct step-growth 
polymerization of D,L-lactic acid without any catalyst. The oligomers obtained, 
designated OLG 1 to 5, appeared clear to slightly yellowish colored and had a liquid, 
waxy or solid consistence depending on the synthesis time, which varied from 4 hours 
to 8 days. Yields were found to be between 56 and 83 %.  
The oligomers were first characterized by end-group analysis, SEC, DSC and 
1
H-
NMR. The obtained molecular and thermal properties are summarized in Table 1. The 
number-average molecular weight ranged from 290 to 1320 Da according to an 
average degree of polymerization from 4 to 18. The DSC experiments showed that all 
polydisperse oligomers are amorphous waxes with glass transition temperatures 
between -17.2 °C and 27.2 °C. This dependence of Tg on molecular weight is well 
known and described e.g. in [36]. Furthermore, it was observed that Tg increased  
 
Table 1. Characterization of polydisperse D,L-lactic acid oligomers 
 
Code nDP
a
 nM
a
 wM
b
 wM / nM
c
 Tg (°C)
d
 LA (%)
a
 attribute 
OLG 1 4 290 280 1.3 -17.2 7.7 liquid 
OLG 2 5 380 430 1.4 3.5 7.3 viscous 
OLG 3 7 540 630 1.6 11.8 4.5 viscous 
OLG 4 11 830 960 1.8 15.6 3.5 solid 
OLG 5 18 1320 1560 2.3 27.2 2.7 solid 
 
a
 obtained by H-NMR 
b
 obtained by end-group analysis 
c
 obtained by SEC 
d
 obtained by DSC 
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strongly at the beginning of polycondensation due to the change in concentration of 
the low molecular weight fraction and water in the reaction mixture. In the course of 
the reaction the molecular weight increased whereas the water content and the 
monomer concentration decreased. 
1
H-NMR was used to determine residual monomer 
in the oligomers [7]. 
The solubility of oligomers which has up to now not been reported was tested in 
various solvents. All oligomers were found to be soluble in acetone, DCM and THF 
but insoluble in petroleum ether, demineralized water and 0.01 N HCl. In phosphate 
buffer at pH 7.4 all oligomers were soluble with the exception of OLG 4 and 5, which 
appeared swollen after 48 hours. The different solubilities in aqueous media result 
from the pka of lactic acid (pka 3.4) [37]. At neutral pH the free carboxylic end group 
is dissociated and forms a salt, which is soluble depending on the molecular weight of 
the oligomer. If the concentration of hydrogen ions increases and reaches values 
below pH 3 the undissociated, more lipophilic free acid function is formed. Ionization 
of the carboxylic end groups was necessary for hydration and solubility. The ratio of 
end-group to oligomer chain length increases with decreasing molecular weight, 
resulting in an increased solubility of oligomer. This ratio reached the highest value in 
OLG 1 ( nM  290 Da) and the smallest in OLG 5 ( nM  1320 Da) which explains the 
obtained differences in solubility. 
3.2 Effect of temperature on degradation kinetics of lactic acid oligomers 
The degradation experiments with D,L-lactic acid oligomers for determination of 
activation energy were carried out in aqueous phosphate solution (pH 7.4) at four 
temperatures (65, 70, 80 and 90 °C). 
The degradation of oligomers resulted in fragments with hydroxylic and carboxylic 
end groups, which finally degraded to the monomer lactic acid. The increase of 
monomer content in the buffer medium was used as an indicator for the extent of 
hydrolysis and was monitored by HPLC. The fraction of oligomers, which has still to 
degrade to the monomer was expressed as remaining monomer. The percentage of 
remaining monomer was plotted against the time on a semi-logarithmic scale. From 
the slope of the plot the hydrolytic cleavage rate constant kobs was calculated. It was 
found that with increasing nDP  the reaction rate constant decreased in parallel with a 
visually observed decrease in solubility of oligomer in the medium. Furthermore, for 
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each oligomer kobs increased with increasing incubation temperature. This temperature 
dependency of the reaction rate is described by the Arrhenius equation (Eq.(2)) as 
follows: 
 
RT
E
lnAlnk
a
obs ??            (2) 
 
where kobs is the observed reaction rate constant, A is the frequency factor and Ea is 
the activation energy, R is the universal gas constant (8.3143 Joule K
-1
 mol
-1
) and T is 
the absolute temperature. Eq. (2) indicates that a graph of ln kobs versus 1/ T is linear 
with a slope of -Ea/ R and an intercept of ln A (Fig. 1). The calculated Ea of hydrolysis 
for four oligomers ranges from 47 to 67 kJ/ mol. The Ea obtained for OLG 5 is similar 
to results reported by Dunn et al. [38] and Makino et al. [6]. However, Ea values in the 
literature vary over a broad range because of dissimilarities in molecular weights and 
polymer composition [39-41]. 
It was found that oligomers having smaller average molecular weights show smaller 
Ea values (47.0, 49.1 and 51.5 kJ/ mol corresponding to OLG 1, 2 and 3). An 
additional explanation could be the higher hydrophilicity of OLG 1, 2 and 3 in 
comparison to OLG 5, being less capable of absorbing water. Swelling through water 
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Figure 1. Arrhenius plots for the degradation rates of various D,L-lactic acid oligomers obtained at 
four incubation temperatures (65, 70, 80 and 90 °C). 
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absorption leads to an increase of the theoretical free volume and chain flexibility 
within the matrix thus facilitating hydrolysis. In consequence less energy of activation 
is necessary to cleave ester bonds. 
3.3 Effect of pH on degradation kinetics and mechanism of hydrolysis 
The effect of pH on the hydrolysis rate constant of various D,L-lactic acid 
oligomers was analyzed by monitoring the release of lactic acid in the surrounding 
medium at 65 °C by HPLC. 
The percentage of remaining monomer was plotted against time in a semi-logarithmic 
scale. From the slope of the line the reaction rate constant (kobs) was obtained. The 
concentration of monomer in the samples increased according to pseudo first-order 
kinetics for the studied pH values and is exemplarily shown for OLG 2 (Fig. 2).  
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Figure 2. Degradation profile of OLG 2 depending on pH at 65 °C 
At all three pH values under investigations, i.e. 1.5, 4.5 and 7.4, monomer release was 
fastest from the smallest oligomer as expected. For all oligomers the monomer release 
was slowest at pH 4.5. These results are in accordance with the mechanism of acid/ 
base catalyzed hydrolysis [6]. The pH profiles of the experimentally determined rate 
constants for various oligomers are shown in Fig. 3. Around the pka value of lactic 
acid (pka 3.4) the reaction rate of oligomers had reached the minimum. This finding is 
in accordance with results obtained in a more detailed investigation of the pH 
dependency of kobs performed by DeJong et al. [25] and Maniar et al. [18]. 
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Our results regarding Ea and the log kobs  pH profile provided evidence for the 
suitability of employing the in vitro monomer release test to investigate the 
degradation kinetics of oligomers as function of pH, temperature and average chain 
length. Due to the fact that this test was based exclusively on the detection of released 
monomer related mainly to the terminal ester bonds it provides limited information on 
the degradation mechanism. 
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Figure 3. Ln kobs-pH profile of D,L-lactic acid oligomers. 
l
H-NMR spectroscopy allows direct monitoring of ester bond cleavage and is capable 
of differentiating exactly between terminal and internal ester bonds.  
In Scheme 1 the degradation of poly(D,L-lactic acid) is described. Four different 
types of methine proton (-CH) signals (? 4.0-5.2 ppm) were identified (Fig. 4) in 
accordance with DeJong et al. [32]. Multiplets at 5.2 ppm, 5.07 ppm and 4.2 ppm 
were assigned to the methine proton signal of internal ester bonds (-CH
a
), ester bonds 
at the carboxylic chain-end (-CH
b
) and ester bonds at the hydroxylic chain end (-CH
c
), 
respectively. The methine proton of free lactic acid (-CH
d
) appeared as quartet at 4.08 
ppm. The abbreviation M is used from now on as synonym for the methine proton 
signals. From the signal intensities the peak area of each methine proton was 
calculated as follows.  
The fraction of total ester bonds (= fraction of unhydrolyzed ester bonds) at a time 
point was obtained from the area ratio of (M1+M2)/ (M1+M2+M3+M4). The fraction of  
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Figure 4. 1H-NMR spectra taken after (a) 0.5 h, (b) 8 h and (c) 24 h of OLG 2 hydrolysis catalyzed by 
0.118 M DCl in ACN-d3. 
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free lactic acid was calculated from the area ratio of M4/ (M1+M2+M3+M4) and the 
fraction of terminal ester bonds resulted from M3/ (M1+M2+M3+M4). During 
degradation occurred a change in these peak areas. The peak area of internal ester 
bonds (M1) decreased while those of terminal ester bonds (M2 and M3) and of free 
lactic acid (M4) increased. By monitoring these changes it is possible to discriminate 
between the mechanism of hydrolysis, i.e. random or chain-end cleavage. If the 
formation of monomer is proportional to loss of ester bonds, chain-end cleavage is the 
mode of hydrolysis. If, in contrast, ester bond cleavage occurs randomly the formation 
of monomers is not proportional to the loss of ester bonds. In consequence nDP  
declines faster than by chain-end hydrolysis.  
In Fig. 5 the fraction of the four methine proton signals of various oligomers at the 
beginning of experiment is shown. It should be emphasized that the initial 
composition obtained in acidic medium was identical to that found under basic 
conditions. The areas of M2 and M3 were similar and ranged from 19 % to 5 % 
depending on the oligomers studied. The fraction of M4 (monomer) was the greatest 
(7.5 %) in the oligomer sample with the lowest average molecular weight and 
decreased with increasing average chain-length to 2 %. 
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Figure 5. Fraction of methine proton signals from various oligomers in ACN-d3 obtained at the 
beginning of experiment. 
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The fraction of M1 (internal ester bonds) was the smallest in OLG 1 and increased 
with raising average molecular weight. 
In Fig. 6a the ratio of methine proton signals obtained in acid (0.118 M DCl) after 24 
h incubation is shown. The fraction of M4 increased depending on nDP  of oligomers  
whereas the fraction of M1 decreased only slightly. It was found that the loss of ester 
bonds was independent from the total ester bonds (E) and followed a pseudo-zero 
order kinetics (Fig. 6b) as given by Eq.(3)  
-d[E]/ dt = k
0
/ DPn
0
           (3) 
where k
0
 is the pseudo-zero order rate constant and DPn
0
 is the initial average degree 
of polymerization. 
The plot of total ester bonds and monomer content versus time is exemplarily shown 
for OLG 4 in Fig. 6c. An excellent linearity (0.9935 ? R² ? 0.9951) over degradation 
time was obtained. The lines run almost parallel and the slopes are similar. In contrast, 
a plot of total ester bonds and terminal ester bonds (sum of M2 and M3) as function of 
time does not show any correlation (Fig. 6c, insert). The zero order degradation data 
obtained under acidic conditions for various oligomers prove that hydrolysis proceeds 
via chain-end cleavage (unzipping) as described by Shih et al. [34]. 
Using N,N-dimethylaminopyridine (DMP) as basic catalyst another hydrolysis 
mechanism was found. The ratio of methine proton signals after 24 h incubation is 
shown in Fig. 7a. The fraction of M1 decreased strongly in parallel with an increase of 
M2 and M3 whereas M4 increased less than under acidic conditions. In contrast to 
results obtained in acidic media it was found that in alkaline media the loss of ester 
bonds depends on the total ester bonds and followed a pseudo-first order kinetics (Fig. 
7b) which is described in Eq.(4) 
-d[E]/ dt = k
1
 E            (4) 
where k
1
 is the pseudo-first order rate constant.  
Moreover, it looks that the plot of total ester bonds and terminal ester bonds versus 
time follow the same profile (Fig. 7c). However, due to the fact that at an infinite 
degradation time only the monomer is left in the H-NMR spectrum, the amount of 
terminal ester bonds should display a maximum before they reduce to zero. Therefore  
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(c) 
Figure 6.  Acid hydrolysis: (a) fraction of methine proton signals from various oligomers after 24 h, (b) 
plot of total ester bonds versus time, (c) OLG 4: plot of total ester bonds and monomer as well as 
terminal ester bonds (Fig. insert) versus time.  
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(c) 
Figure 7. Basic hydrolysis: (a) fraction of methine proton signals from various oligomers after 24 h, (b) 
plot of ln total ester bonds versus time, (c) OLG 4: plot of total ester bonds and terminal ester bonds as 
well as monomer (Fig. insert) versus time.  
45 
Hydrolytic degradation of D,L-lactic acid oligomers 
 
the plot of terminal ester bonds versus time can not be continuously linear or follow 
1st order kinetics. 
Since it is most likely that under the applied conditions cyclic dimers were formed as 
intermediate during hydrolysis [25] which show a peak at the same chemical shift as 
the methine protone signal near the terminal carboxylic acid bonds, the plot in Fig 7 c 
compares not only the formation rate of terminal ester bonds but also the formation 
rate of cyclic lactides with the degradation rate of total ester bonds. The lines run 
parallel with similar slopes which suggest that the hydrolysis of oligomers occurs not 
by a chain-end cleavage. Moreover, it seems that degradation under basic conditions 
proceeds by backbiting at the chain ends as described by DeJong et al. [25] and not 
really randomly as proposed for e.g. poly(lactic acid) [35].  
As shown in Fig. 7c, insert the number of total ester bonds decreased faster than the 
formation rate of monomer which is probably due to random ester cleavage. However 
it can also be explained by the formation of cyclic lactides by the backbiting 
mechanism. 
As previously mentioned, a random ester cleavage leads to a faster decline of nDP  
because hydrolysis under alkaline conditions is irreversible. Under acidic conditions 
hydrolysis is reversible and therefore somewhat slower. Furthermore, chain-end 
cleavage reduces the polymer chain length step by step about one monomer only. In 
contrast, random ester cleavage cuts the polymer chain randomly i.e. anywhere in the 
chain, thus reducing nDP  evidently. In consequence, nDP  declines faster.  
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Figure 8. Plot of absolute nDP  versus the time as function of catalyst for OLG 5. 
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However, it should be mentioned that the degradation rate is highly pH-dependent and 
therefore the difference can be ascribed also to pH and not only to the mechanism. 
Fig. 8 shows the decrease of nDP  versus the time depending on the catalyst 
exemplarily for OLG 4.  
4. Conclusion 
To investigate the relationship between oligomer molecular weight and polymer 
degradation, low molecular weight oligo(D,L-lactic acid)s of various molecular 
weights ( nM  290 to 1320 Da) have been synthesized and fully characterized.  
The solubility of various polydisperse oligomers was determined via direct 
measurements. It was found that the solubility of oligomers depends on both pH and 
average molecular weight. Polydisperse oligomers with nM  smaller than 830 Da are 
soluble in buffer at pH 7.4 whereas oligomers of nM  ? 830 Da are insoluble. 
The kinetic studies showed that the hydrolysis rate of all tested oligomers was the 
slowest at pH 4.5. The energy of activation ranged from 47 to 67 kJ/ mol depending 
on average molecular weight of oligomers.  
From the mechanistic study utilizing 
1
H-NMR spectroscopy it could be conducted that 
the oligomer degradation mechanism is dependent on the pH of the surrounding 
medium. Under acidic conditions chain-end cleavage is the mode of action whereas 
under basic conditions degradation of oligomers occur via random ester cleavage and/ 
or backbiting.  
Typically, in a medium of pH 7.4, the pH inside the bulk drops due to the formation 
of free carboxylic acid groups which cannot leach out the bulk. In contrast pH at the 
surface remains unchanged because of the buffer capacity and the exchange of buffer 
in the in vitro model. According to the theory of bulk degradation, hydrolysis should 
be faster in the inner part than at the surface due to the higher concentration of ester 
and carboxyl bonds resulting in the inner part in a lower pH value (the so-called 
autocatalytic effect).  
Our results clearly demonstrate that hydrolysis slows down with decreasing pH values 
up to a pH of approximately 4.5 and once the pH is lower than 4.5 hydrolysis speeds 
up again. These results indicate that at least in the initial degradation stage the 
degradation was not dominated by the so-called autocatalytic effect.  
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Results generated in our studies demonstrate the need to investigate other factors than 
pH to better understand and explain the bulk degradation nature of PLA and PLGA 
since pH has proven to play only a minor role. 
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Abstract 
Oligomers are thought to accelerate the hydrolytic degradation of devices prepared 
from poly(lactide-co-glycolide), PLGA, due to their increased number of carboxylic 
end groups compared to polymer. To experimentally verify this hypothesis, two D,L-
lactic acid oligomers having molecular weights close to their critical limit of solubility 
were synthesized and incorporated into PLGA films in three concentrations (0, 10 and 
30 % w/ w). 
All films were translucent, rather flexible and initially amorphous. With increasing 
oligomer concentration the glass transition temperature (Tg) and the molecular weight 
of films decreased prior to erosion. 
The degradation studies show that initial mass loss and water absorption are increased 
in oligomer-containing films as a function of average molecular weight and oligomer 
concentration. However, the incorporation of oligomers does not accelerate the 
degradation of films. By contrast, oligomer-containing films show extended lag-phase 
until onset of polymer erosion. This was shown to be related to crystallization as 
observed in parallel. Moreover, it was found that crystallization occurs earlier in 
oligomer-containing films and that the degree of crystallization is related to the 
average molecular weight of the oligomer. These findings bring new insight into the 
role of oligomers in the degradation process and can be used to explain why erosion in 
massive polymer devices occurs from the center to the surface.  
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1. Introduction 
Poly(lactide-co-glycolide) (PLGA) is one of the most frequently studied class of 
biodegradable polymers, especially for controlled delivery of peptides [1, 2] and 
proteins [3, 4]. The major advantage of these polymers is that they do not require 
surgical removal after completion of drug release.  
The degradation of aliphatic polyesters has been investigated by numerous authors. It 
is generally accepted that PLGA, and their homopolymers polylactic acid (PLA) and 
polyglycolic acid (PGA) degrade via bulk hydrolysis of ester bonds [5, 6, 7]. Finally, 
their constituent monomers lactic and glycolic acid are formed which are eliminated 
by metabolic pathways [8]. It has been shown that the degradation rate is affected by 
several physical and chemical factors, such as initial pH, ionic strength and 
temperature of external medium, copolymer ratio, molecular weight, crystallinity and 
specimen size [9, 10, 11]. 
However, until now the degradation process has not been completely understood. 
From a general point of view, two phenomena are discussed. Firstly, degradation 
causes an increase of the number of carboxylic end groups, which are known to 
autocatalyze ester hydrolysis [12, 13, 14]. Secondly, with increasing degradation time 
the amount of oligomer within the polymer matrix increases and soluble oligomers 
can escape from the whole mass of device. In larger specimens only soluble oligomers 
which are located close to the surface can diffuse from the matrix before they are 
totally degraded, whereas oligomers located more inside the matrix remain entrapped 
and increase the acidity within the matrix. The encapsulated oligomers increase the 
concentration of ester and carboxyl bonds, which results in an increased degradation 
rate and autocatalysis with respect to the outer part of the specimen. These diffusion-
reaction phenomenona [15, 16, 17] lead to a differentiation between surface and 
center in larger specimen [7, 9, 18]. Recently new parameters have been identified 
which contribute to the bulk erosion process [19, 20].  
Although oligomers play an important role in the complex bulk degradation 
mechanism only few authors have studied their influence on degradation kinetics [21, 
22]. However, the molecular weight of low molecular weight polymers studied was 
far away from their critical limit of solubility [23, 24]. Due to the fact that this 
parameter is important with respect to their effect on polymer degradation [25, 26] 
54 
Hydrolytic degradation: Effect of oligomers 
 
only limited information can be obtained from previous studies about the role of 
oligomers in this process.  
For this reason a series of D,L-lactic acid oligomers were synthesized and 
characterized with regard to solubility, degradation rate and degradation mechanism 
[26]. Two oligomers having average molecular weights close to their critical limit of 
solubility were selected and incorporated into PLGA films in different concentrations 
(0, 10 and 30 % w/ w).  
The intention of the present study was to test the hypothesis that oligomers 
autocatalyze the degradation process [12, 13, 14]. If oligomers increase the polymer 
degradation rate the lifetime of the oligomer-containing PLGA films should be shorter 
than the lifetime of the oligomer-free PLGA film.  
In consideration of the fact that until now crystallization caused by PLGA degradation 
has never been investigated as a function of the oligomer, the main interest was 
focused on this issue.  
2. Experimentals 
2.1 Materials 
D,L-lactic acid oligomers (OLA) were synthesized by polycondensation of 90 % D,L-
lactic acid aqueous solution without any catalyst as described previously [26]. Briefly, 
90 % D,L-lactic acid aqueous solution was allowed to concentrate by gentle 
distillation of water. The reaction started at normal pressure and was then changed to 
reduced pressure after removal of water. The temperature was slowly increased to 
reach 140 °C after 3 days. The polydisperse oligomers obtained had weight average 
molecular weights ( wM ) of 1700 Da (OLA-1) and 3200 Da (OLA-2). 
Uncapped poly(lactide-co-glycolide) (PLGA), Type Resomer® RG 503H, lactide/ 
glycolide ratio 50:50, wM  27.4 kDa, was purchased from Boehringer Ingelheim, 
Ingelheim, Germany. All organic solvents were HPLC grade and provided from 
Merck, Darmstadt, Germany. 
2.2 Preparation of films 
All films were prepared by a solvent casting method. Briefly, 0, 10 or 30 % w/ w of 
OLA-1 or OLA-2 were added to PLGA and dissolved in 10 ml acetone. The solution 
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was poured into a Teflon® mould and the solvent was allowed to evaporated at 8 °C 
for 24 hours. The films were then dried under vacuum at room temperature to remove 
residual solvent until a constant weight was obtained. The resulting films had a 
thickness of about 200 - 250 µm and were cut into disks of 11-mm diameter using a 
punch. The final weight of films was 16.4 ? 0.96 mg (n = 30). 
2.3 Determination of molecular weight 
The average molecular weight was determined by size exclusion chromatography 
(SEC) using polystyrene standards (Mw 400 to 2.5?106 Da) (Polymer Standard 
Service, Mainz, Germany) for calibration. The samples were dissolved in 
tetrahydrofuran (THF) and filtered before injection. THF containing 0.1 % 
trifluoracetic acid (TFA) was used as mobile phase at a flow rate of 1 ml/ min. Two 
PSS® columns, 7.8 x 300 mm, with a pore size of 103 Å and 105 Å (Polymer Standard 
Service, Mainz, Germany) connected in series were used to separate sample fractions 
at 30 °C. A differential refractometer (ERC 7510, Tokyo, Japan) was used for 
detection. Each sample was analyzed in duplicate and data were processed using 
ChromStar 4.1® software (SCPA, Stuhr, Germany). 
2.4 Determination of glass transition temperature 
Measurement of glass transition temperature (Tg) was performed using a differential 
scanning calorimeter (DSC 821, Mettler Toledo, Greifensee, Switzerland). Two 
samples (4-7 mg) were heated twice under nitrogen atmosphere. Thermograms 
covering a range of -20 °C to 200 °C were recorded at a heating or cooling rate of 10 
K/ min. Calibration of the system was performed using gallium and indium standards. 
The onset temperature, which corresponds to the temperature at which the signal first 
derives from baseline was used to describe the phase transition and was evaluated 
from the second heating run (STARe® software 6.0, Mettler Toledo, Greifensee, 
Switzerland). 
2.5 X-ray diffraction (XRD) 
X-ray diffraction patterns were recorded with an automatic powder diffractometer D 
5000® (Siemens, Munich, Germany) using a CuK? radiation source (40 kV, 30 mA) 
and a nickel filter (1.54 Å). The scanning speed was 0.2 degree/ min. The maximum 
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scattering angle (2?) was 35°. Separate blank patterns were recorded to allow 
subtraction of air-scattering and sample holder. Sharp peaks or broad halos were 
observed in diffraction pattern of crystalline or amorphous film, respectively. 
Crystallinity was calculated using DiffracPlus 3.0® software (Bruker, Rheinstetten, 
Germany).  
2.6 Degradation studies 
Weighed film specimens were placed in previously weighed glass vials and immersed 
in 12 ml phosphate puffer (0.05 M, pH 7.4 containing 0.05 % benzalconium chloride 
and 0.1 % sodium azide). The samples were incubated at 37 °C for 4 weeks without 
agitation. Six parallel samples were tested for each type of film. The buffer solution 
was replaced after each sampling time in order to prevent pH changes due to polymer 
degradation. At different time-intervals, the films were removed, washed threefold 
with water and weighed after removal of surface water. The samples were then dried 
for at least 48 h in a lyophilizer.  
Water absorption and mass loss were calculated using the following equations: 
Water absorption (%) = 100 (Ww-Wd)/ Wd 
Mass loss (%) = 100 (W0 -Wd)/ W0 
where Ww and Wd represent the mass of film in wet and dry state, respectively.W0 is 
the film weight determined initially.  
SEC and DSC were applied to monitor the degradation of films whereas XRD was 
used to detect crystallinity in degraded polymer films. 
3. Results and discussion 
3.1 Physicochemical characteristics of PLGA/OLA films 
Using the solvent-casting technique, five different PLGA films were produced. The 
properties of applied materials are listed in Table 1.  
In order to clarify the miscibility of PLGA and D,L-lactic acid oligomer all films were 
analyzed by DSC. The presence of a single Tg in all blends confirmed that PLGA and 
oligo-D,L-lactides are miscible at all the given composition. Miscibility was also 
observed at higher oligomer concentrations, however, the mechanical strength of 
resulting films was insufficient.  
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All films were characterized prior to erosion and results are summarized in Table 2. 
The acronyms are reflecting the nature of each film matrix.  
The addition of low molecular weight oligomers resulted in a decrease of molecular 
weight of the films produced. 
Table 1.  Characteristics of materials used 
Molecular weight (kDa) Code 
wM  nM  
wM / nM  Tg (°C) 
OLA-1 1.7 0.96 1.8 15.6 
OLA-2 3.2 1.5 2.1 26.8 
PLGA 27.4 16.0 1.7 44.5 
Table 2.  Compositions and characteristics of produced PLGA films 
Composition 
(%) 
Molecular  
weight (kDa) 
Code Oligomer 
PLGA OLA wM  nM  
wM / 
nM  
Tg 
(°C) 
Reference None 100 0 24.7 14.4 1.7 44.3 
PLGA/OLA-1 10 % OLA-1 90 10 19.6 5.6 3.5 40.7 
PLGA/OLA-1 30 % OLA-1 70 30 16.8 3.3 5.2 34.0 
PLGA/OLA-2 10 % OLA-2 90 10 20.9 7.1 2.9 42.6 
PLGA/OLA-2 30 % OLA-2 70 30 18.4 5.4 3.4 36.5 
This results mainly from the mixing of different molecular weights and less from 
degradation caused by incorporated oligomers [21].  
It was observed that the number average molecular weight ( nM ) of oligomer-
containing films decreased more than wM . This can be explained by the fact that nM  
depends more on the fraction of low molecular weight than on the fraction of high 
molecular weight. 
In parallel the polydispersity index (PI) increased in oligomer-containing films. The 
PI is defined as the ratio of wM  to nM  and describes the broadness of molecular 
weight distribution within a polymer. From Table 2 it can be seen that PI is a function 
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of oligomer loading and of the average molecular weight of oligomer. The higher the 
oligomer loading and the lower wM  of oligomer the higher PI of film.  
3.2 In vitro degradation profiles 
The films listed in Table 2 were incubated in phosphate buffer pH 7.4 at 37 °C. As 
degradation parameters water absorption, mass loss (both gravimetrically) and weight 
loss (SEC) were monitored. Morphological changes were detected by DSC and X-ray 
diffraction. 
3.2.1 Visual examination 
All prepared films were initially translucent and elastic depending on average 
molecular weight and percentage of oligomer in the film matrix. After one of day 
incubation all films were white and no longer translucent. With increasing incubation 
time the diameter of all films increased dramatically. After freeze-drying all films 
were waxy-like, wavy and brittle. 
3.2.2 Water absorption and glass transition temperature 
Water absorption was detected from beginning of incubation in buffer (Fig. 1a). The 
initial amount of absorbed water was a function of average molecular weight of 
oligomer and their percentage in PLGA film. Water absorption of all films increased 
steadily with time because degradation causes an increase in polymer hydrophilicity. 
The incorporation of oligomers increases the hydrophilicity of the film due to their 
hydroxylic and carboxylic end groups. In consequence, oligomer-containing films 
absorbed more water than the oligomer-free film. 
For PLGA/OLA-1 10 and 30 % the amount of water absorbed after 3 days was 186 
and 240 %, respectively, compared to 41 % in oligomer-free film as reference (Fig. 
1a). However, after 5 days water absorption was higher in the PLGA/OLA-1 10 % 
film than in PLGA/OLA-1 30% film. We assume that with an increasing amount of 
oligomer incorporated the leaching out of OLA-1 increases and consequently the 
hydrophilicity of the remaining film decreases. 
On the other hand with rising oligomer chain length the hydrophilicity of oligomer 
decreased due to its increased number of hydrophobic methyl groups. Thus more time 
is needed to degrade the oligomer in a soluble state. In consequence degradation of  
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Figure 1. Effect of addition of oligomers (0, 10 and 30 %) on water absorption of PLGA 50:50 films 
during in vitro degradation: (a) for OLA-1 and (b) for OLA-2. The five types of films are presented in 
Table 2 
polymers of the same chemical composition but different molecular weights is slower 
for the higher molecular weight compound [27]. 
Comparing OLA-1 and OLA-2 the first has a lower average molecular weight and 
glass transition temperature whereas the latter is more lipophilic. Therefore initial 
water uptake was reduced in films containing OLA-2. For PLGA/OLA-2 10 and 30 % 
the amount of water absorbed after 3 days was only 47 and 180 %, respectively (Fig. 
1b).  
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Table 3 Glass transition temperature of degraded PLGA films 
 Tg (°C) 
Sample 0 d 3 d 5 d 7 d 10 d 14 d 18 d 21 d 
PLGA 44.3 40.7 39.2 37.2 35.1 36.3 41.7 45.5 
PLGA/OLA-1 10% 40.7 39.0 37.6 35.3 33.9 41.1 46.2 46.2 
PLGA/OLA-1 30% 34.2 40.3 37.2 34.6 33.8 29.7 44.4 40.5 
PLGA/OLA-2 10% 42.6 38.5 37.7 36.6 35.6 31.9 43.9 39.1 
PLGA/OLA-2 30% 36.5 39.7 38.5 38.0 36.3 38.3 41.7 40.2 
As expected water absorption of PLGA/OLA-2 films was a function of oligomer 
loading over the whole time period. 
In parallel to water absorption the glass transition temperature of films was monitored 
as a function of oligomer molecular weight and oligomer loading during degradation 
(Table 3). It is known that a decrease of wM  leads to a decrease of Tg which is 
attributed to an easier chain mobility in polymers [17]. From Table 3 it can be seen 
that Tg decreased directly after incubation in buffer with one exception due to polymer 
degradation and water absorption [25, 28]. For PLGA films, containing 30 % OLA-1 
or OLA-2 an increase of Tg was observed after 3 days. This was caused by diffusion 
of a major part of the incorporated oligomers out of the film. The remaining higher 
molecular weight fraction is characterized by a higher Tg as known from literature 
[29].  
Surprisingly Tg started to increase in all films after 10 or 14 days and reached values 
greater than those in the beginning [30]. In parallel with the observed increase of Tg 
an endothermic peak was detected in the first run of DSC experiment (Fig. 2). This 
was assigned to the melting of crystalline domains formed during degradation [15, 
30]. X-ray diffraction was successfully used to confirm this assumption. All results 
demonstrated that incorporation of oligomers in PLGA film clearly enhanced their 
hydrophilicity [31].  
3.2.3 Crystallinity 
In all films no crystallinity was found at the beginning of degradation studies. The 
XRD pattern of initial films is exemplary shown for PLGA/OLA-2 10 % (Fig. 3a).  
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Figure 2. DSC thermograms obtained after 14 days immersion in buffer pH 7.4: (a) PLGA/OLA-1 10 
%, (b) PLGA/OLA-2 10 % and (c) reference. AU means area units. 
The obtained halo pattern is typical for an amorphous polymeric compound and 
confirmed that all films were initially amorphous.  
However, after 2 weeks of incubation crystallinity was detected in 10 % oligomer-
containing films indicating that oligomers contribute to morphological changes during 
degradation. This can be explained by the fact that with increasing water content, 
molecule chains in the polymer matrix become more flexible and mobile enough to 
crystallize under such conditions [29, 32].  
It was found that the degree of crystallinity was higher in films containing OLA-1 
( wM  1700 Da) instead of OLA-2 ( wM  3200 Da) (Table 4). Based on this finding we 
conclude that the degree of crystallinity at this time point was depending on the 
average molecular weight of oligomer added. With increasing incubation time 
crystallization occurred also in reference and 30 % oligomer-containing films. The 
diffraction pattern of oligomer-free and oligomer-containing films obtained after 18 
days of incubation are shown in Fig. 3b and Fig. 3c. Five sharp peaks were detected 
(2? = 16.9, 18.9, 21.9, 27.7 and 32.6°) which demonstrated the presence of crystalline 
domains within all polymer films. As expected crystallinity was higher in oligomer-
containing films confirming our hypothesis that oligomers affect directly or indirectly 
crystallization during degradation (Table 4).  
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Figure 3. X-ray diffraction pattern obtained for (a) PLGA/OLA-1 10 % before immersion, (b) 
reference and (c) PLGA/OLA-1 10 % after 18 days immersion in buffer pH 7.4. 
Unfortunately, after 3 weeks no X-ray pattern could be obtained due to the very small 
amounts of residual polymer mass. 
The results show that the degree of crystallinity in oligomer-containing films depends 
on average molecular weight and percentage of incorporated oligomer. One can 
hypothesize that this finding is related to the differences in Tg and molecular weight 
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Table 4 Crystallinity of degraded PLGA films 
Crystallinity (%) 
Code 
0 d 10 d 14 d 18 d 
Reference 0 0 0 22 
PLGA/OLA-1 10 % 0 0 26 28 
PLGA/OLA-1 30 % 0 0 0 34 
PLGA/OLA-2 10 % 0 0 15 31 
PLGA/OLA-2 30 % 0 0 0 20 
between the two oligomers. These should influence the chain mobility and the 
reorganization of chains within the film [33].  
However, crystallization was only observed at later stages of polymer degradation. 
The driving force for such morphological change is a closer packing of polymer 
chains with consequent enhancement of intermolecular attraction [29].  
3.2.4 Mass loss and molecular weight changes 
The wM  of oligomer-free film decreased with time (Fig. 4). In contrast wM  of 
oligomer-containing film was either unchanged (10 % OLA) or increased (30 % 
OLA) within the first 24 hours. Due to the higher average molecular weight of OLA-2 
the increase of wM  observed was smaller than for OLA-1 containing films. Beyond 
this wM  of all blends decreased with time as expected and reached a plateau after 2 
weeks. This can be explained by the fact that films degrading for longer than 10 days 
in buffer, were partially insoluble in THF and thus excluded from analysis. In addition 
degradation products, which are small enough to be soluble, diffused out from the 
film and were also excluded from the analysis. As a consequence no further decline of 
wM  was observed until the end of the study. However, the best representation of the 
molecular weight progression is the polydispersity index.  
As shown in Fig. 5a, the PI (closed symbols) of PLGA/OLA-1 10 and 30 % decreased 
from 3.5 and 4.3 to 2.1 and 2.6, respectively within the first 3 days. In contrast PI of 
reference increased slightly within these first days indicating that a smaller molecular 
weight fraction was formed.  
Mass loss of films (open symbols, Fig. 5) was observed immediately after incubation 
in buffer. 
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Figure 4. Degradation profiles of oligomer-free and oligomer-containing films which are presented in 
Table 2. 
In general mass loss was higher for films containing OLA-1 due to its smaller wM  
and consequently higher solubility. As expected initial mass loss increased with 
increasing amount of incorporated oligomer. 
The initial mass losses were 8, 12 and 21 % for reference, PLGA/OLA-1 10 and 30 
%, respectively (Fig. 5a). This can be assigned to the release of both residual acetone 
and incorporated oligomer. The initial mass loss observed, as well as the reduction of 
PI, confirmed our assumption that a great amount of low molecular weight fraction 
had left the film matrix within 3 days. 
No remarkable mass loss was detected until the end of the week. After 10 days mass 
loss had reached 22, 24 and 30 % compared to 15, 14 and 21 % after 1 week for 
reference, PLGA/OLA-1 10 and 30 %. The PI of these films decreased in combination 
with a loss of wM , as shown in Fig. 4., indicating that most of the higher molecular 
weight fraction and incorporated oligomer were degraded and had partially left the 
film matrix. After 14 days mass loss of oligomer-free film was accelerated in 
comparison to 18 days found for PLGA/OLA-1 10 and 30 % films. 
In Fig. 5b mass loss and changes in molar weight distribution of PLGA/OLA-2 10 and 
30 % are shown. No differences were found between initial mass loss of reference and 
PLGA/OLA-2 10 % compared to a slightly increased mass loss of PLGA/OLA-2 30 
% during the first 5 days. In parallel PI decreased from 2.95 and 3.45 to 2.3 and 2.5 
for PLGA/OLA-2 10 and 30 %, respectively. Mass loss increased after 1 week from 
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10 and 17 % to 25 and 32 % after 10 days for PLGA/OLA-2 10 and 30 %, 
respectively, and was rather constant until day 18. From then on mass loss of 
PLGA/OLA-2 10 and 30 % was accelerated which was also found for films 
containing OLA-1. At the end of the study the remaining mass of all films was less 
than 5 %.  
In summary, for all oligomer-containing films a prolonged lag phase up to the onset of 
accelerated mass loss was observed. This observation leads to the assumption that the 
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Figure 5 Effect of addition of oligomers (0, 10 and 30 %) on mass loss (open symbols) and 
polydispersity (closed symbols) of PLGA films: (a) PLGA/OLA-1 and (b) PLGA/OLA-2. 
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during of lag phase is influenced by oligomers. The extent to which degradation is 
affected depends on both the average molecular weight of the oligomer incorporated 
and the amount of remaining oligomer. 
4. Conclusion 
The influence of the average molecular weight and the concentration of D,L-lactic 
acid oligomers added on the degradation rate and crystallinity of PLGA 50:50 film 
was investigated. The incorporation of polydisperse oligomers clearly enhanced the 
hydrophilicity of PLGA film. The initial mass loss and the amount of water absorbed 
were functions of average molecular weight and concentration of oligomer. For the 
same oligomer initial mass loss and water uptake was enhanced with increasing 
amount of oligomer in the film. However, an autocatalytic effect caused by the 
increased number of carboxylic end groups due to the incorporation of oligomers was 
not observed.  
The degradation studies point to the fact that all initially amorphous polymer films 
changed into semi-crystalline films. Moreover, it was found that oligomers contribute 
to such morphological change due to their properties like low Tg, short chain length, 
low wM  and hydrophilicity that facilitate crystallization. It was found that the time 
until crystallization occurred, as well as the degree of crystallization, depends on the 
average molecular weight of oligomers added and their remaining concentration in the 
film.  
During this study no differentiation between surface and center was observed due to 
the small specimen size. However, the finding that oligomers cause direct or indirect 
crystallization during degradation of an initially amorphous PLGA matrix can be used 
to explain the surface/ center differentiation in large specimen in accordance with 
described diffusion-reaction phenomenona. In further studies the influence of 
oligomers on degradation rate and crystallinity in massive polymer devices will be 
assessed to test this hypothesis. A challenge for the future will be to visualize the 
distribution of oligomers incorporated during the degradation process. 
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Abstract 
In the present study, a less known polyester based on tartaric acid was characterized 
with respect to its degradation mechanism. Poly(2,3-(1,4-diethyl tartrate)-co-2,3-
isopropyliden tartrate) (PTA) differs from commonly used biodegradable polyesters, 
such as poly(lactides-co-glycolides) (PLGA) by the presence of additional cleavable 
bonds in the polymer side chains 
This modification results in different polymer properties and influences polymer 
degradation. The hydrolytic degradation of PTA was studied in parallel to PLGA 
using disc-shape matrices which were obtained by compression-molding. The discs 
were incubated in pH 7.4 phosphate buffer solution at 37 °C. The degraded samples 
were characterized for percentage mass loss, water absorption, decay of molecular 
weight and change in glass transition temperature. The results demonstrate that the 
degradation of PTA proceeds via bulk erosion similar to PLGA. However, the 
degradation of PTA implants is characterized by a rapid mass loss within a short 
period of time appearing after a definite lag phase without remarkable mass loss. This 
makes the polymer promising for pulsatile drug release systems.  
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1. Introduction  
Biodegradable polymers have gained importance in the development of controlled 
release devices. A number of biodegradable polymers have been synthesized and 
evaluated for their potential use as drug delivery system. Major interest in this area 
has focused on aliphatic polyesters such as polylactide-co-glycolides (PLGA) and 
their homopolymers due to the favorable toxicology of their degradation products [1]. 
The degradation of these polymers occurs via hydrolytic ester bond cleavage, leading 
to a decrease in their molecular weight [2-5]. The molecular architecture of the 
polymer influences among other things the in vitro degradation properties which 
should be related to the release properties of the polymer. 
In the present study, the degradation of a less known tartaric acid-based polyester 
(polytartrate) was studied. Poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden 
tartrate) (PTA) is a branched polytartrate and was first described in 1991 [6, 7]. Early 
experiments using this polymer revealed the suitability of this material for preparation 
of microparticles and its suitability for controlled release of peptides [8, 9]. In contrast 
to PLGA having all hydrolytic sensitive ester bonds located in the polymer main 
chain, PTA contains additionally ester as well as ketal groups in the polymer side 
chains. This affects the properties of PTA especially the degradation velocity which 
determines the type of polymer erosion.  
In general, polymer erosion can be classified into homogeneous or bulk erosion, and 
heterogeneous or surface erosion [10]. However, it should be mentioned that both are 
extremes and that the erosion mechanism of a polymer device is often characterized 
by a combination of both. 
Surface eroding polymers contain e.g. highly labile bonds (polyanhydride) or acid-
labile bonds (polyorthoesters) in their polymer main chain, which degrade very fast in 
contact with water. Thus the degradation rate on the surface is much faster than the 
penetration rate of water into the polymer bulk. In consequence erosion is limited to 
the surface and drug release is degradation controlled [11]. This behavior changes if 
degradation rate is slower than the rate of water diffusion into the device. In this case 
water penetrates into the bulk and degradation occurs throughout the polymer (bulk 
erosion). The resulting pores and channels in the matrix influences the rates of 
polymer degradation and drug release [12]. Therefore, predicting and controlling the 
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release kinetics of drugs from bulk eroding polymers like PLGA is very difficult and 
surface eroding polymers are preferred. 
The aim of this study was to investigate the degradation behavior of PTA with respect 
to its degradation mechanism, which has not been published before. Since studying 
the effect of device size on degradation rate can provide insight into the degradation 
mechanism of polymer [13, 14] three different sizes of PTA disc-shaped matrices 
were examined to determine if primarily surface or bulk erosion occured. The 
hydrolytic degradation in pH 7.4 phosphate buffer solution was monitored by 
molecular weight decay, mass loss, water absorption, change in glass transition 
temperature and monomer release. Finally the degradation and mechanism of PTA 
and PLGA matrices of identical size were investigated in a comparative study.  
2. Materials and Methods 
2.1 Materials 
Poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden tartrate) (PTA) was received from 
Aventis R&T, Frankfurt, Germany. The molecular structure is shown in Fig. 1. 
Poly(D,L-lactide-co-glycolide) (PLGA), copolymer ratio 50:50, Type 
Resomer
®
RG502H was purchased from Boehringer Ingelheim, Ingelheim, Germany. 
Tetrahydrofuran (THF), trifluoroacetic acid (TFA), methylene chloride, acetonitrile-d3 
(ACN-d3), and the buffer chemicals were purchased from Merck, Darmstadt, 
Germany.  
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Figure 1. Structure of PTA 
2.2 Characterization of polymer 
2.2.1 
1
H-NMR 
1
H-NMR spectra of PTA were recorded on a Bruker spectrometer operating at 500 
MHz at room temperature (16 scans). 20 mg of polymer was dissolved in ACN-d3, 
filtrated and transferred into a NMR tube (approximately 1.8 ml) to determine 
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polymer composition. Chemical shifts (?) were expressed in ppm with respect to the 
ACN-d3 signal at 1.96 ppm: CH3 -triplet at 1.26 ppm, CH3 -singulet at 1.45 ppm, CH2 
quadruplet at 4.2 ppm, CH singulet at 5.05 ppm and CH singulet at 5.82 ppm [15].  
2.2.2 Size exclusion chromatography (SEC) 
The molecular weight was determined by size exclusion chromatography using 
twostyragel columns (PSS guard column SDV, PSS SDV 100, 5 µm, PSS SDV linear 
M, 10 µm, 300 x 7.5 mm, Polymer Standard Service, Mainz, Germany). Degassed 
THF containing 0.1 % (v/ v) trifluoroacetic acid (TFA) was used as mobile phase at a 
flow rate of 1 ml/ min. A polymer aliquot (n=3) was dissolved in THF (20 mg/ ml) 
and filtrated before injection. The weight average molecular weight ( wM ) and the 
number average molecular weight ( nM ) were calculated relative to polystyrene 
standards (Polymer Standard Service, Mainz, Germany) using refractive index 
detection (ERC 7510, Tokyo, Japan) at 30 °C. Each sample was analyzed in duplicate 
and data were processed using ChromStar 4.1
®
 software (SCPA, Stuhr, Germany). 
2.2.3 Differential scanning calorimetry (DSC) 
Measurement of glass transition temperature (Tg) was performed using a differential 
scanning calorimeter (DSC 821, Mettler Toledo, Greifensee, CH). Two samples (~ 7 
mg) of polymer were heated twice under nitrogen atmosphere. Thermograms covering 
a range from  60 to 200 °C were recorded at a heating and cooling rate of 10 K/ min. 
Calibration of the system was performed using gallium and indium standards. The 
onset temperature which corresponds to the temperature at which the signal first 
derives from baseline was used to describe the phase transition and was evaluated 
from the second heating run (STARe
®
 software 6.0, Mettler Toledo, Greifensee, 
Switzerland). 
2.3 Preparation of polymer matrices 
Disc-shaped matrices were prepared by compression molding at room temperature 
under appropriate pressure using a single punch excenter press (EK 0, Korsch Berlin, 
Germany) instrumented with a strain gauge for compression force measurements 
(Catman
®
 2.1, Hottinger Baldwin Messtechnik, Darmstadt, Germany). The polymer 
powder (size ? 500 µm) was compressed using two flat-faced punches of 3, 5 or 7 
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mm in diameter. The powder for each disc was weighed on an analytical balance and 
manually filled into the die. The compaction load (maximum upper punch pressure) 
was adjusted such that the same force was applied for each disc. The thickness of the 
discs obtained was 1.57±0.07 mm and the weight was 14, 40 or 86 mg, respectively.  
2.4 In vitro degradation 
The weighed implants were placed into weighed glass vials and 12 ml phosphate 
buffer (0.05 M, pH 7.4 containing 0.05 % benzalkonium chloride and 0.1 % sodium 
azide) were added. Samples were incubated at 37 °C without agitation for 4 weeks 
and occasionally shaken (twice/week) for 15 seconds. After various time-periods four 
implants were removed, washed with demineralized water and lyophilized. The buffer 
solution was replaced after each sampling in order to prevent pH changes due to 
polymer degradation. The degree of polymer degradation was measured by SEC and 
DSC. Mass loss (ML) and water absorption (WA) were determined gravimetrically 
using the following equations: 
(1) ML (%) = 100 x (W0 -Wd)/ W0 
(2) WA (%) = 100 x (Ww-Wd)/ Wd 
where W0 is the implant weight determined initially, Ww is the wet weight of implant 
and Wd the weight of implant after lyophilization. 
2.5 Monomer release 
PTA discs (n = 3), 7 mm in diameter, were placed into vials, 6 ml phosphate buffer 
(0.05 M, pH 7.4 containing 0.05 % benzalkonium chloride and 0.1 % sodium azide) 
were added and the vials were sealed with a crimping cap. Samples were incubated at 
37 °C without agitation as described previously. At predetermined time points the 
medium was completely removed with a syringe and transferred into an empty sealed 
crimping vial. Fresh medium was added to the sample through the vial septum using a 
syringe. The removed medium was analyzed for the amount of monomeric 
degradation products. The concentration of L-tartaric acid released in the medium was 
measured by HPLC (Waters 2690, Waters Corporation, Milford, M.A.). Separation 
was performed on a C18 column (225 x 4 mm I.D., Machery Nagel, Düren, Germany) 
at 30 °C. Sulfuric acid solution of pH 2.5 was used as mobile phase at a flow rate of 
0.35 ml/ min [16]. Detection was performed using a Waters 2470 programmable 
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absorbance detector (Waters Corporation, Milford, USA) operating at 215 nm. 
Calibration curves were generated from known concentrations of L-tartaric acid in 
release medium. The detection limit was 1 µg/ ml. The Millenium 32
®
 
chromatography manager, version 4.0 (Waters Corporation, Milford, USA) was used 
to analyze the data. 
The concentration of acetone and ethanol in the release medium was analyzed using a 
gas chromatography system equipped with a flame ionization detector attached to a 
Headspace sampler (HP 5890, Hewlett Packard, Germany). The temperatures were 
selected as follows: oven temperature 80 °C, injector temperature 150 °C and detector 
temperature 200 °C. The chromatograph was fitted with a 50 m x 0.32 mm i.d. CP-
SIL 5CB column coated with 5 ?m film of stationary phase (Chrompack, Middleburg, 
The Netherlands) [17].  
2.6 Photomicrography of PTA matrices 
The degradation of PTA matrices was visualized using a photo camera (EOS 30, 
Canon, Germany) adapted with a 70-300 mm lens (Voigtländer, Fürth, Germany) for 
macroscopic view. Additionally lyophilized polymer matrices were investigated 
microscopically (Axioplan stereo microscope, Zeiss, Jena, Germany) before and after 
degradation. Photographs of the surfaces and cross-sections of polymer matrix were 
recorded using a digital microscope camera (DP 10, Olympus, Hamburg, Germany). 
3. Results and discussion 
3.1 Polymer characteristics 
The representative 
1
H-NMR spectrum of poly(2,3-(1,4-diethyl tartrate)-co-2,3-
isopropyliden tartrate) is shown in Fig. 2 and the structure of the polymer was 
confirmed by the peak assignments. The 
1
H-NMR signals of 2,3-isopropylidentartrat 
(monomer 1) were found at 1.45 ppm (-C(CH3)2) and at 5.05 ppm (-CH). The signals 
of 1,3-diethyltartrat (monomer 2) resonated at 1.26 ppm (-CH2CH3), at 4.2 ppm (-
CH2CH3) and 5.82 ppm (-CH). The molar composition was determined by comparing 
the methyl signal of monomer 1 at 1.45 ppm and the methylene signal of monomer 2 
at 1.26 ppm and calculated as 50 to 50. As consequence of the polycondensation the 
series of monomers is strictly alternating.  
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Figure 2. 1H-NMR spectra and structure of poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden 
tartrate) (PTA).  
The average molecular weight of PTA calculated from polystyrene standards was 
found to be 23 kDa. The polymer is amorphous and characterized by a glass transition 
temperature of 41.9 °C. The thermal properties of PTA are similar to PLGA 50:50 (Tg 
40.5°C). Solubility studies demonstrated that PTA is soluble e.g. in acetone, THF, 
methylene chloride and acetonitrile but insoluble in water, petroleum ether and 
ethanol. 
3.2 In vitro degradation 
3.2.1 Influence of matrix size on in vitro degradation 
In order to determine the influence of matrix size on degradation rate, PTA discs of 
three different diameters 3, 5 and 7 mm, were examined in buffer at pH 7.4.  
It was hypothesized that if pure surface erosion occurs degradation is limited to the 
outer surface and degradation time is directly proportional to device size. In contrast, 
if bulk erosion occurs degradation is independent from device size leading to similar 
degradation rates [18]. 
The effect of matrix size on water absorption and molecular weight decay is shown in 
Fig. 3a. Due to the lipophilic methyl and ethyl groups in the polymer side chains the 
polymer is hydrophobic and hence no water can be absorbed initially. The measured 
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water uptake of less than 6 % w/w immediately after incubation in buffer results from 
penetration of water into the pores of the device. As known the polymer particles 
undergo plastic deformation under compression and the porosity of the matrix 
depends on the densification of the polymer particles decreasing with increasing 
compression force [19]. Since the matrices were compressed at high compaction load 
below the glass transition temperature of the applied polymer it is likely that the 
implant porosity is only a few percents. By weighting out the same amount of 
polymer and applying the same compaction load a reproducible porosity of discs can 
be assumed. 
The absorption of water increases obviously after 7 days for 3 mm discs and after 10 
days for 5 and 7 mm discs. This observation can be explained by the fact that 
hydrolysis occurs within the polymer matrix forming free carboxylic and hydroxylic 
end groups which increase the hydrophilicity of the polymer. It was found that the 
absorption rate was a function of matrix size increasing with decreasing matrix size. 
This finding is related to the specific surface of polymer matrices which decreases 
with increasing disc diameter. 
Although only small amounts of water were absorbed initially the wM  of all polymer 
matrices decreased linear with time without any lag phase and independent from disc 
size. This proves that degradation proceeds immediately after incubation in buffer. 
After 2 weeks the wM  of polymer matrices was dramatically decreased to values 
below 2000 Da. We assume that during degradation soluble oligomers were formed 
which are able to diffuse out of the polymer matrix which is already known for PLGA 
and PLA matrices [  ].  
The mass loss profile as function of matrix size is shown in Fig. 3b. The erosion of 
PTA discs occurred after a definite lag phase although the molecular weight decay 
was observed from the beginning. The onset time of mass loss increased slightly with 
increasing matrix size. However, the rate of mass loss was similar for all discs of 
different size, indicating the predominance of bulk erosion. In general mass loss 
occurred in parallel with an increase in water absorption. As seen from Fig. 3b the 
molecular weight at this time point dropped below 2000 Da and confirms our 
assumption that at this time degradation products became soluble and diffused out of 
the polymer matrix into the release medium leading to the mass loss of polymer 
matrix. It is interesting to note that PTA matrices lost a great amount of their mass  
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Figure 3. In vitro degradation of PTA matrices in buffer at pH 7.4: Effect of matrix size on water 
absorption (a) molecular weight decay (a), mass loss (b) and glass transition temperature (c).  
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within a short period of time. The remaining polymer mass eroded afterwards 
completely at a slower rate until the end of the study. 
Additionally to water uptake, molecular weight decay and mass loss, the glass 
transition temperature was monitored during degradation (Fig. 3c). During the first 
week the glass transition temperature decreased slowly independent from matrix size 
due to the decrease in molecular weight. In parallel with an increase of water 
absorption and molecular weight decay Tg dropped fast and rather constantly to small 
values until the end of the study. The decrease of Tg is a result of both, absorption of 
water and formation of low molecular weight degradation products.  
3.2.2 Monomer release 
In order to gain more information about the degradation of PTA the release of the 
final degradation products tartaric acid, acetone and ethanol was monitored. The 
differential release profiles (Fig. 4) show an initial period of 10 days where only small 
amounts (< 1 ppm) of ethanol and acetone were released (Fig. 4, insert). The 
concentration of tartaric acid in the release medium was up to this time point below 
the limit of detection (< 1 µg/ml). The fact that only few amounts of monomeric 
degradation products were found initially is attributed to the time required for 
hydrolysis to produce sufficient amounts of monomers. 
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Figure 4. In vitro degradation of PTA: release of acetone, ethanol and L-tartaric acid from PTA 
matrices, 7 mm diameter  
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In parallel with an increase in water absorption the amount of tartaric acid, acetone 
and ethanol in the release medium started to raise. The concentration of tartaric acid, 
ethanol and acetone increased slowly on day 13 and 14 but thereafter a remarkable 
increase of monomers in the release medium was observed. The highest concentration 
of acetone and tartaric acid were found at day 21. It can be seen that the amount of 
ethanol released after defined time intervals was in general higher than those of 
acetone with exception of day 21. It can be assumed that a great amount of the ketal 
bonds were already cleaved at this time whereas some diethylester bonds were still 
unhydrolyzed. When comparing these results with the mass loss profile it can be seen 
that the onset time of mass loss correlates with the onset time of monomer release. 
Furthermore, the rate of monomer release was the highest from day 14 until day 21 
which is in accordance with the rate of the mass loss at this time period.  
3.2.3 Photomicrography of polymer matrices 
In order to visualize the degradation process of PTA matrices the discs were observed 
and photographed during the degradation study (Fig. 5-7).  
Immediately after immersion of polymer matrix in buffer a lot of bubbles were 
observed at the device surface which disappeared rather completely within 1 week 
(Fig. 5 a, b). As seen clearly, the polymer matrix did not swell until day 10 but 
thereafter in parallel with remarkable increase of water absorption the shape of the 
polymer matrix changed dramatically from a flat disc to a bloated convex device (Fig. 
5c, d). Within few days the polymer shell bursted (Fig. 5e) and soluble degradation 
 
a b c d
e f g h
 
Figure 5. Photomicrographs of the PTA disc during in vitro degradation: after (a) 3 days (b) 7 
days, (c) 10 days, (d) 11days, (e)14 days (f) 18 days, (g) 21 days and (h) 26 days. 
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Figure 6. Surface-center differentiation of PTA matrices after degradation in buffer pH 7.4. Left 
column: cross section of lyophilized samples, right column: surface of lyophilized samples. From top to 
bottom: after 0, 3, 5, 7 and 10 days. 
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products such as oligomers and monomers were released into the medium as 
evidenced by the monomer release results which are in accordance with the onset of 
mass loss. The remaining polymer mass collapsed, resulting in a round device of 
reduced polymer mass, and degraded completely until week 4 (Fig. 5 f-h).  
To obtain information about internal morphological changes the polymer matrix was 
removed at various time intervals, lyophilized and sectioned (Fig. 6). Additionally, the 
interest was focused on the surface characteristic of degraded matrix. Prior to erosion 
the matrix surface appeared slightly rough and less porous. 
The cross section of the polymer matrix shows that the internal structure is also dense 
and homogenous (Fig. 6 a, b). After 3 days immersion in buffer, bubbles and blisters 
not present at the beginning are visible on the surface of the device (Fig. 6 d). Some of 
these blisters become to holes during the first week (Fig. 6 f, h) which were then 
closed likely by swelling at day 10. It can be seen that the surface is very smooth and 
appeared translucent at this time point (Fig. 6 k). Interestingly, the cross section of 
polymer matrix at day 3 shows a transparent glassy core and a white intransparent 
outer region (Fig. 6 c). Furthermore, it can be seen that the glassy core contains  
 
a
zoom
 
Figure 7. Burst of PTA matrix during degradation: (a) image of lyophilized sample at day 13 and 
magnification of matrix shell (zoom) 
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Figure 8. Photomicrographs of PTA matrix obtained in buffer at day 3 (a, c) and after adding 50 ?l 
of a acetone-containing buffer solution on the surface of the implant (b, d) 
several air inclusions whereas only few pores are present close to the surface (Fig. 6 
c-i). 
The differentiation between surface and center became more obvious with increasing 
incubation time. The thickness of the white polymer layer decreased whereas the part 
of glassy polymer inside the polymer matrix increased (Fig. 6 c-i). Unfortunately it 
was no longer possible to observe the polymer matrices microscopically due to the 
burst of device between day 12 and 14. However, photographs of a polymer matrix 
lacerating during lyophilization show internal a glassy, swollen polymer mass and a 
surrounding thin white shell (Fig. 7). 
As shown previously ethanol, acetone and tartaric acid are degradation products 
whose concentrations raise during degradation. However, only acetone is able to 
dissolve the polymer and induce surface changes as observed during degradation of 
polymer matrices (Fig. 8).  
Based on all findings we hypothesis that the degradation of PTA discs proceeds as 
follows: After immersion of polymer matrix in buffer only small amounts of water 
penetrate into the device due to the low porosity of the polymer matrix and the 
initially hydrophobic character of the polymer. As a consequence of water penetration 
into the pores of device hydrolysis is not limited to the surface and occurs also in 
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polymer bulk. However, the penetration of water into device pores is strongly affected 
by mean pore size and pore size distribution which depends on compression force 
during matrix preparation [20, 21]. Due to the inhomogeneity of compression process 
the density distribution in the disc-shaped device is heterogeneous [22-24]. 
Furthermore, as the polymer has a relatively low glass transition temperature it is 
likely that particles which were in direct contact to the compression tool were sintered 
as consequence of friction energy occurring during compression and ejection of 
device [19, 25]. Therefore it is assumed that after placing the polymer matrix in buffer 
the amount of absorbed water in the center of the device is higher than near the 
surface. However, already small amounts of water have a noticeable plasticising effect 
leading to a reduction of the glass transition temperature of polymer [26]. This effect 
explains the observation that already after 3 days a glassy core was found inside the 
PTA discs. Bubbles located within the glassy core result from air embedded in the 
polymer matrix during the compression process.  
With increasing degradation time the part of glassy polymer region increases most 
likely due to the ongoing hydrolysis that causes an increase in acetone and ethanol 
which act as plasticizer. In parallel, the molecular weight decreases and the 
hydrophilicity of polymer raises due to the formation of free hydroxylic and 
carboxylic end groups. As consequence the polymer is able to absorb water and thus 
short polymer chains become flexible. The resulting swelling of polymer causes the 
change in device shape. However, based on the assumption that the border areas of 
polymer matrix were sintered due to friction energy during ejection of device 
horizontal swelling is more complicated. This could explain the bloating of polymer 
matrix. With increasing degradation time the amount of small chain fragments 
increases and the resulting inner pressure causes the burst of implant shell between 
day 12 and 14. The enclosed soluble degradation products diffuse into the surrounding 
medium and mass loss occurs rapidly. The remaining insoluble polymer mass 
concentrates to reduce its surface area and degrades rather constantly until the end of 
the study.  
3.2.4 Comparative study: PTA vs. PLGA 
The aim of this study was to compare the erosion of PTA and PLGA disc-shaped 
matrices. One parameter of interest was the onset of polymer erosion depending on 
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polymer used for manufacturing of matrices. Due to the molecular architecture of the 
PTA it is likely that matrices made of PTA will differ in their erosion and degradation 
behavior compared to PLGA. In order to verify this assumption two batches of PTA 
and PLGA discs (code 1 and 2), 5 mm in diameter, were prepared under the same 
conditions. Since it is known that heat treatment of polymer matrices effect more the 
release characteristics than the degradation the discs were not tempered ?27?. The in 
vitro degradation was evaluated separately and mass loss was taken as a measure for 
the erosion process. 
For PLGA it is widely accepted that degradation in humid atmosphere occurs via 
random scission of ester linkages which are located exclusively in the polymer 
backbone. In general, the degradation process involves three steps: penetration of 
water into the device, secondly the hydrolysis of ester bonds in the polymer main 
chain leading to water soluble degradation products and the mass loss of the device 
through transport of degradation products into the surrounding medium. Due to the 
fact that PTA contains also cleavable bonds in the polymer side chains, degradation is 
not limited to the polymer main chain and occurs also in the side chains of polymer.  
As a consequence of the hydrophobic character PTA matrices did not show a 
remarkable water absorption until day 10 whereas PLGA matrices started water 
absorption directly after immersion in buffer (Fig. 9a). It was found that PTA matrices 
absorb less water than PLGA matrices. Furthermore, the swelling behavior of the 
PTA matrix was different compared to PLGA. Whereas the first tended to increase  
 
Table 1 Molecular weight decay of PTA and PLGA matrices, 5 mm in diameter, 
during incubation in buffer at pH 7.4 
 
Molecular weight ( wM ) (Da) Time 
(weeks) PTA-1 PTA-2 PLGA-1 PLGA-2 
0 23600 23000 10400 11000 
1 13400 12950 4900 5300 
2 2000 1950 3900 4250 
3 1000 1000 3900 4100 
4 < 1000 < 1000 4050 3950 
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Figure 9. In vitro degradation of PTA and PLGA discs, 5mm in diameter (reproduceability study): 
water absorption (a), mass loss (b) and glass transition temperature (c).  
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more in height than in diameter the latter increased obviously in diameter and less in 
height. 
The degradation of both polymers started without any lag phase during the first days 
and decreased linear with time (Table 1). The wM  of PLGA matrix reached a plateau 
after 2 weeks, which was related to two facts: Firstly, PLGA matrices which degraded 
longer than 10 days in buffer were partially insoluble in THF but only the soluble 
portion of degraded matrices could be analyzed. Secondly, from this time point small 
oligomers and monomers formed during degradation became mobile enough to 
diffuse out of the polymer matrix and were excluded from analysis. In consequence, 
no further decline of wM  was observed for PLGA matrices.  
In contrast, all degraded PTA samples were soluble in THF and therefore degradation 
products with wM > 1000 Da could be detected in the samples.  
As generally known the molecular weight has to be reduced substantially to permit 
mass loss through solubilization. Thus, mass loss is an index for the content of water- 
soluble degradation products. 
The mass loss profiles of PTA and PLGA matrices are shown in Fig. 9 b. It can be 
seen that mass loss of PLGA matrices started directly after incubation in water and 
decreased linear with time. In contrast, no remarkable mass loss was observed for  
PTA matrices until day 10. Thereafter an accelerated mass loss was observed. The 
mass of polymer matrix decreased from 98 % at day 10 to 33 % at day 18. (Fig. 9 b). 
The remaining polymer mass degraded rather constantly until the end of the study.  
Finally, the glass transition temperature was monitored as index for polymer 
degradation and water absorption. It can be seen in Fig. 9 c that Tg of PLGA discs 
increased initially which can be assigned to the release of low molecular weight 
compounds. Thereafter Tg declined slowly reaching values near 30 °C after 3 weeks. 
A different behavior was observed for PTA discs. The Tg of PTA discs declined 
slowly from the beginning until day 10. Thereafter the glass transition temperature 
dropped very fast to small values (< 5 °C). This can be assigned to degradation 
products like acetone and ethanol which act as plasticizer. It is also possible that 
oligomeric degradation products which are characterized by a very low Tg contribute 
to the decrease of Tg. 
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4. Conclusion 
Poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden tartrate), a less known 
biodegradable polyester was characterized in vitro. The degradation of polymer 
matrices was investigated in order to determine the erosion mechanism of of this 
polymer.  
Acetone, ethanol and tartaric acid were identified as final degradation products which 
proves that degradation occurs in parallel in the polymer main chain and in the 
polymer side chains. During degradation the initially hydrophobic polymer changed 
into a hydrophilic one thus water absorption occurs subsequent to polymer hydrolysis. 
The results show that under the tested conditions PTA matrices undergo bulk erosion 
rather than surface erosion similar to PLGA matrices which were investigated in 
parallel.  
During degradation a differentiation between surface and center was observed as 
described for massive devices made of PLGA and PLA. However, it has been shown 
that the degradation profile of PTA is different to those obtained from PLGA 
matrices. Surprisingly, the degradation of PTA matrices was characterized by a phase 
of rapid mass loss which appeared after a definite lag phase without any mass loss. 
This feature makes this polymer promising for pulsatile release and further studies are 
necessary to investigate drug release from PTA matrices. 
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Abstract 
In this study a less well known, biodegradable polyester, poly(2,3-(1,4-diethyl 
tartrate)-co-2,3-isopropyliden tartrate, (PTA) was investigated as pulsatile release 
agent.  
PTA implants, containing the LH-RH analogue buserelin, were prepared by 
compression molding. The effect of drug loading, implant size and admixing of 
polymers or excipients on drug release was investigated in vitro (pH 7.4, 37 °C).  
In vitro studies show a multiphasic release profile charaterized by an initial burst 
which is followed by a lag phase. Thereafter, in contrast to common polyesters like 
poly(lactide-co-glycolide) (PLGA) a great amount of drug is released within a short 
period of time (second burst). The remaining drug is released rather constantly until 
the polymer is totally degraded. It was found that the initial burst increased 
concurrently with drug loading in contrast to the second burst which increased with 
decreasing drug loading. Furthermore, it could be shown that the second burst can be 
modified or supressed by blending PTA with other polymers or excipients.  
Based on our results PTA has been identified as promising biodegradable polymer for 
pulsatile drug release. 
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1. Introduction 
For many drugs a pulsatile release system, where the drug is released in intervals is 
advantageous and desired. The development of such a delivery system is of 
considerable interest, e.g. for vaccines and hormones [1-3]. 
In general vaccines are administered as an initial injection of antigen followed by 
repeated injections (booster shots) at least two or three times. This is necessary to 
re-expose the immune system to an antigen and to enhance the extend of an immune 
response [4].  
However, especially in the animal health industry repeated administration of a drug is 
a challenge because the treatment of large or free ranging herds of animals, e.g. cattle 
or sheep, is both a logistical and economical problem. In addition, each administration 
stresses the animals, which increases their susceptibility to diseases and causes 
adverse side effects at the injection side such as fibrous reactions. For these reasons a 
delivery system that releases vaccines in a way that a second treatment for the booster 
immunization is not required (single-shot vaccine), offers numerous benefits and is 
therefore highly requested from the markets [5].  
Based on the knowledge of hormone secretion the development of a pulsatile release 
device for hormones is also of growing interest in animal and human health. The 
release of hormones in a pulsatile manner mimics the physiological pattern of 
hormone secretion and can be used for example in veterinary field for animal 
reproduction and breeding due to control of estrus . 
Since estrus is only a short period of sexual receptivity in female animals where 
ovulation and insemination takes place it is difficult to detect. Thus the pulsatile 
release of hormones could synchronize the estrus to make female animals fertilizable 
at a predetermined time schedule, which is beneficial for livestock producers and for 
breeders [6]. 
In the past, pulsatile drug release in animals was achieved with implanted mechanical 
pumps or non-degradable controlled release systems [3]. At present particulate 
delivery systems based on biodegradable polymers, like poly(D,L-lactide-co-
glycolide) (PLGA) or poly(?-caprolactone) have been investigated as delivery system 
for vaccines and hormones. A single administration of different microspheres caused 
a pulsatile-like release profile. The release profile is adjustable via molecular weight, 
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polymer type, copolymer ratio and particle size of applied microspheres. Due to their 
different degradation rate drug is released at different time points [7-10].  
However, microspheres do not release the booster dose as a sharp bolus, which is 
required especially for effective immunization. The main reason therefore is the 
degradation behavior of polymer on which the release profile is based on [11].  
The intention of this study was to investigate the potential use of poly(2,3-(1,4-diethyl 
tartrate)-co-2,3-isopropyliden tartrate) (PTA), a copolymeric polytartrate, as pulsatile 
release agent and to develop a biodegradable implant which is able to release vaccines 
or hormones in sharp boluses in two separate phases. PTA was selected due to its 
chemical architecture. In contrast to PLGA the polymer contains not only ester groups 
located in polymer backbone but also ester as well as ketal groups in polymer side 
chains [12]. Thus degradation can occur concomitant or successively in polymer main 
chain and polymer side chains which influences the degradation rate and in 
consequence the release behavior of PTA implants.  
2. Materials and Methods 
2.1 Materials 
Poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden tartrate) (Figure 1) was received 
from Aventis R&T, Frankfurt, Germany. PLGA, copolymer ratio 50:50 ( wM  41 kDa) 
and poly(L-lactic acid) (PLA, wM  2000 Da) were purchased from Boehringer 
Ingelheim, Ingelheim, Germany. Magnesium stearate, tetrahydrofurane (THF), 
trifluoroacetic acid (TFA) and all further chemicals were purchased from Merck, 
Darmstadt, Germany. Buserelin acetate, Mw 1350 Da was obtained from Intervet 
International, Unterschleißheim, Germany. 
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Figure 1 Poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden tartrate) 
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2.2 Molecular weight determination 
The molecular weight was determined by size exclusion chromatography using two 
styragel columns (PSS guard column SDV, PSS SDV 100, 5 µm, PSS SDV linear M, 
10 µm, 300 x 7.5 mm, Polymer Standard Service, Mainz, Germany). Degassed THF 
containing 0.1 % (v/ v) trifluoroacetic acid (TFA) was used as mobile phase at a flow 
rate of 1 ml/ min. A polymer aliquot (n=3) was dissolved in THF (20 mg/ ml) and 
filtrated before injection. The weight average molecular weight ( wM ) and the number 
average molecular weight ( nM ) were calculated relative to polystyrene standards 
(Polymer Standard Service, Mainz, Germany) using refractive index detection (ERC 
7510, Tokyo, Japan) at 30 °C. Each sample was analyzed in duplicate and data were 
processed using ChromStar 4.1
®
 software (SCPA, Stuhr, Germany). 
2.3 Thermal analysis 
Measurement of glass transition temperature (Tg) was performed using a differential 
scanning calorimeter (DSC 821, Mettler Toledo, Greifensee, CH). Two samples (~ 7 
mg) of polymer were heated twice under nitrogen atmosphere. Thermograms covering 
a range from  60 to 200 °C were recorded at a heating and cooling rate of 10 K/ min. 
Calibration of the system was performed using gallium and indium standards. The 
onset temperature which corresponds to the temperature at which the signal first 
deviates from baseline was used to describe the phase transition and was evaluated 
from the second heating run (STARe
®
 software 6.0, Mettler Toledo, Greifensee, 
Switzerland). 
2.4 Preparation of implants 
Buserelin acetate and polymer powder (? 500 µm) were triturated in an agate mortar. 
Mixtures with different drug loadings (DL) were compressed at room temperature 
with appropriate pressure using two cylindrical flat-faced punches of 3 or 5 mm in 
diameter on a single punch excenter press (Korsch EK 0, Berlin, Germany). Implant 
weight was 14 or 40 mg, respectively.  
The additive-containing implants were prepared in the same manner using a physical 
mixture of PTA and additional compound. The final drug polymer mixtures consisted 
10 % buserelin by weight.  
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2.5 In vitro release 
The weighed implants were placed into glass vials and 12 ml phosphate puffer (0.05 
M, pH 7.4, containing 0.05 % benzalkonium chloride and 0.1% sodium azide) were 
added. The surfactant was used to minimize the adsorption of the peptide on the glass 
walls. Samples were incubated at 37 °C for 4 weeks without agitation. At defined time 
points 8 ml of the release medium were withdrawn and replaced by fresh buffer. 
Samples were analyzed for buserelin content using RP-HPLC. Separation was 
performed on a C18 column, 225 x 4 mm i.d. (Machery Nagel, Düren, Germany) at 
42 °C. The mobile phase consisted of a mixture of buffer, pH 2.5 (triethylamine-
containing phosphoric acid solution) and acetonitrile. The flow rate was 1 ml/ min. 
Detection was performed using a Waters 2470 programmable absorbance detector 
(Waters Corporation, Milford, USA) operating at 216 nm. Calibration curve was 
generated from known concentrations of buserelin acetate in mobile phase. The 
detection limit was 1 µg/ ml. The Millenium 32
®
 chromatography manager, version 
4.0 (Waters Corporation, Milford, USA) was used to analyze the data. 
2.6 In vitro degradation 
The in vitro degradation of pure PTA implants was studied under the same conditions 
as for in vitro release described above.  
The weighed implants (n=4) were placed into weighted glass vials and 12 ml 
phosphate buffer (0.05 M, pH 7.4 containing 0.05 % benzalkonium chloride and 0.1 
% sodium azide) were added. Samples were incubated at 37 °C without agitation for 4 
weeks. After various time-periods four implants were removed, washed with 
demineralized water and lyophilized. The buffer solution was replaced after each 
sampling in order to prevent pH changes due to polymer degradation. The degree of 
polymer degradation was measured by SEC and DSC. Mass loss (ML) and water 
absorption (WA) were determined gravimetrically using the following equations: 
(1) ML (%) = 100 x (W0 -Wd)/ W0 
(2) WA (%) = 100 x (Ww-Wd)/ Wd 
where W0 is the implant weight determined initially, Ww is the wet weight of implant 
and Wd the weight of implant after lyophilization. 
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3. Results and discussion 
The objective of this work was to investigate the potential use of poly(2,3-(1,4-diethyl 
tartrate)-co-2,3-isopropyliden tartrate) (Fig. 1) as pulsatile release agent. Implants 
were selected for their ease of manufacturing without the need to apply heat or 
organic solvents, which might reduce the activity of the drug. The size of the 
subcutaneous implant was selected in such a way that an administration through a 
wide-bore needle is possible. 
An important factor in the design of a delivery system is the relative drug loading [13-
15]. In order to evaluate the influence of drug loading on the release profile, the in 
vitro release from implants with various drug loadings (1, 5 and 10 % w/ w) was 
studied in buffer pH 7.4 at 37 °C.  
Fig. 2 shows the daily and cumulative release profiles obtained from 3 mm implants at 
three different drug loadings. The multiphase release profile is characterized by an 
initial burst increasing concurrently with drug loading, releasing 5 to 25 % of drug 
within 24 hours. The initial burst can be attributed to the immediate release of 
buserelin entrapped at the implant surface. With decreasing drug loading the 
probability decreases that drug particles are situated on or near the surface thus the 
magnitude of initial burst is smaller. After 48 hours the initial burst was terminated 
and a secondary phase occurred, in which hardly any drug is released (lag phase). 
This can be explained by the fact that buserelin will be released mainly through water 
filled pores and channels. However, due to the chemical structure of PTA the polymer 
is initially lipophilic and only less pores formed by polymer densification during 
implant preparation are available for drug release. With increasing incubation time the 
lipophilic side chains, e.g. diethyl tartrate, were cleaved leading to an increase in 
polymer hydrophilicity and water absorption.  
The fact that initially released buserelin creates also pores and channels for water 
absorption which facilitates hydrolysis, explains the small differences in the duration 
of lag phase. Depending on drug loading the lag phase lasted between 9 and 11 days 
until the second burst occurred. Within this third phase of release profile a great 
amount of drug is released as sharp peak and it was found that the extent of second 
burst (booster dose) is related to drug loading and increases with decreasing drug 
loading. This can be explained with the lower initial burst and the resulting higher 
remaining drug content in implants of lower drug loading. 
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Figure 2 Differential (a) and cumulative (b) in vitro release of buserelin from PTA implants, 3mm 
in diameter in buffer at pH 7.4: effect of drug loading.  
The linear relationship between initial and second burst shown in Fig. 3 and allows 
the adjustment of the booster dose. It was found that the second burst occurred after a 
dramatic change of implant shape. In parallel with an increase in water absorption the 
implant shape changed from a flat disc to a bloaded convex device. Within few days 
the polymer shell lacerated and the booster dose was released rapidly within 2-3 days. 
Afterwards, the remaining polymer mass released the remaining drug rather 
constantly at a slow release rate until the end of the study. 
Another variable that is known to affect drug release is the implant size [16-18]. 
Therefore implants of 3 mm and 5 mm in diameter containing 10 % w/ w drug were 
prepared and their in vitro release behavior was evaluated (Fig. 4 a, b).  
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Figure 3 Cumulative in vitro release of buserelin from PTA implants, 3 mm in diameter in buffer 
(pH 7.4, 37 °C): Effect of drug loading on initial and second burst  
A reduction of implant diameter resulted in an increase of initial burst (15 vs. 21 %) 
according to results published in literatur [19-21]. 
However, the overall release profile remained unchanged and a second burst was 
observed after a defined time intervall. It was found that the degree of the second 
burst as well as the amount of drug released thereafter increased with increasing 
implant size.  
The drug release profile obtained from PTA implants is different to those reported for 
PLGA or PLA devices. The drug release from these polymer systems occurs in a 
triphasic manner, characterized by an initial burst, a lag phase where only small 
amounts of drug were released and a phase of increased drug release due to polymer 
erosion. During the polymer erosion phase a great amount of drug is released rather 
constantly over a longer time period. In contrast PTA implants released a great 
amount of drug within few days and the remaining drug is released at a lower release 
rate until the end of the study. 
The observed second burst may be induced by polymer degradation. To verify this 
assumption the degradation of placebo PTA implants was evaluated under the same 
conditions as for the verum PTA samples. As generally known, the polymer 
molecular mass has to be reduced substantially to permit mass loss through 
solubilization [22-24]. 
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Figure 4  Differential (a) and cumulative (b) in vitro release of buserelin from PTA implants, 10 % 
drug loading, in buffer (pH 7.4, 37 °C): effect of implant diameter 
From Fig. 5 it can be seen that the molecular weight decreased immediately after 
immersion of implants. However, neither mass loss nor water absorption were 
observed at the beginning. This can be explained by the fact that the rather lipophilic 
PTA contains hydrolysis labile bonds in both polymer backbone and polymer side 
chains [25]. During hydrolysis free acid functions as well as hydroxyl groups are 
formed which increase the hydrophilicity of the polymer and therefore facilitate water 
absorption. In consequence water absorption and mass loss commence after 7 days. 
After 2 weeks the molecular weight of remaining implant was dramatically decreased. 
This caused a further increase of implant permeability and hydrophilicity resulting in 
an accelerated mass loss. The implant mass decreased from 78 % at day 14 to 12 % at 
day 22 within one week. The remaining polymer mass was completely degraded until 
the end of the month. 
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Figure 5 Mass loss (?), wM  decrease (?), water absorption (?) and cumulative drug release (?) 
of PTA placebo implants (?, ?, ?) and 10 % buserelin-containing implants (?). 
The coincidence in degradation and release profils (Fig. 5) suggests that the second 
burst is mainly caused by polymer degradation. It was observed that both mass loss 
and release of booster dose occurred rapidly and in parallel with the elevation of 
implant shell. This can be explained by the fact that during degradation the molecular 
weight decreases whereas the polymer hydrophilicity raises due to the formation of 
hydroxylic and carboxylic end groups. As consequence water absorption increases 
and hence short polymer chains become flexible which causes the observed change in 
polymer shape. Based on the assumption that the implant borders are sintered due to 
fact that during preparation of implants polymer particles which were in direct contact 
to the compression tool were exposed to friction energy, the degradation products are 
enclosed within the polymer devices [26, 27]. With increasing degradation time the 
amount of small flexible chain fragments increases and the resulting inner pressure 
causes the elevation of implant shell.  
The lag time before onset of implant bursting will depend on the polymer molecular 
weight, the copolymer ratio of applied PTA, the porosity and the size of the implant. 
Indeed, the induction period of PTA 3 mm was about 7 days, whereas it took 10 days 
for 5 mm implants (Thesis, Chapter 4). Furthermore, the physicochemical properties 
of drug will influence the degradation and finally the release profile. For hydrophobic 
drugs or compounds it is less likely that they dissolve in water and diffuse out of 
device due to their poor solubility. In consequence, less pores and channels will be 
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formed which could facilitate the absorption of water. Thus more time is needed to 
degrade the polymer and the second burst will occur at a later time point. In parallel 
with increasing molecular weight of PTA the time until implant bursting occurs will 
increase. 
However, also admixing of polymers or excipients will affect the release profile. 
Therefore PLGA and PLA which differ in molecular size, hydrophilicity and sterical 
features were incorporated into PTA implants (10 % w/ w) and their effect on initial 
burst and booster dose was evaluated. Whereas PLGA is amorph and rather 
hydrophilic the latter is crystalline and more lipophilic than PLGA. Their glass 
transition and melting temperatures depend on molecular weight and polymer 
composition.  
Based on preliminary test with aggregated lactose as model substance, which was 
released within 24 hours due to its excellent solubility, it was necessary to select a 
lipophilic water insoluble model substance. Thus magnesium stearate (Mg-sterate) 
which is commonly used as lubricant in a concentration range between 0.1 and 1 %  
w/ w was incorporated into the implant (10 % w/ w). After incubation of implant Mg-
stearate located at the surface should be washed out to leave pores in the implant 
through which the drug can be released.  
Buserelin, which is water-soluble will primarily be released through water filled pores 
and channels and less through a hydrophobic polymer matrix like PTA [28]. 
Leachable molecules, like Mg-stearate, will enhance drug release from the 
hydrophobic matrix. The results of in vitro release are summarized in Table 1. 
The admixing of Mg-stearate resulted in an increase of initial burst from 24.0 to 39.5 
% as expected and confirmed our assumption that a part of Mg-stearate is leached out 
and resulting pores increases drug release. In contrast the addition of PLGA leaded to 
a similar initial burst (22.8 vs. 24.0 %).  
On the other side, the incorporation of the low molecular weight lipophilic and 
crystalline L-PLA resulted in an small increase of initial burst (24.0 vs. 29.2 %). 
Nevertheless, independent on incorporated materials the initial burst was followed by 
an extended lag phase until day 10.  
The release of the booster dose was depending on incorporated material. It was found 
that incorporation of PLGA decreased the release rate during the second burst, most 
probably by swelling due to its high hydrophilicity compared to PTA.  
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Table 1 Drug release of different PTA implants containing 10 % w/ w buserelin 
Drug release [µg] 
Initial burst Second burst Implant 
day 1 
 
day 11 day 12 day 13 day 14 total 
PTA 296  10.7 149.0 107.7 48.6 316.0 
PTA/ Mg-stearate 643  9.9 22.8 32.8 41.7 107.2 
PTA/ PLGA 335  10.6 61.2 106.2 84.8 262.8 
PTA/ L-PLA  367  18.9 41.7 49.7 47.9 158.2 
In contrast implants containing L-PLA or Mg-stearate did not show bursting of 
implant and no drug was released in a pulsatile manner. We assume that pores within 
the device which result either from leaching out of Mg-stearate or by diffusion of 
soluble degradation products of L-PLA prevent the accumulation of PTA degradation 
products that are responsible for the bursting of implant.  
4. Conclusion 
In this study poly(2,3-(1,4-diethyl tartrate)-co-2,3-isopropyliden tartrate) was 
identified as promising biodegradable polymer for pulsatile drug delivery.  
The advantage of this polymer compared to other polyesters like PLGA is its 
degradation behavior which results in bursting of implant after a definite time point. 
This allows the release of a great amount of drug within a short period of time after a 
definite lag phase where no drug is released and can be used for delivering drugs in a 
pulsatile manner. 
The influence of the most important parameters like drug loading and implant size on 
drug release were investigated in this study. As expected, initial burst increased with 
increasing drug loading and decreasing implant size. All implants showed a second 
burst which was indirect proportional to initial burst. This allows the adjustment of 
the booster dose.  
Moreover, the incorporation of polymers or leachable excipients like Mg-stearate can 
be used either to modify extent of secondary burst and the time at which implant 
bursting occurs or to inhibit this behaviour.  
In the future other parameters have to be investigated such as molecular weight or 
copolymer ratio for achieving a bursting of implant at a predefined time point in a 
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range of days or weeks. Indeed, a challenge will be to achieve a uniform drug release 
during the bursting of implant. Nevertheless alternative depot formulations such as 
microparticles or in-situ implants could be prepared from PTA and their release 
characteristics could be investigated as alternative to implants. 
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Abstract 
Here we investigated the possibilty to develop different levels of correlation between 
in vitro drug release profiles and in vivo pharmacokinetic parameters for three 
Buserelin implant formulations. The in vitro and in vivo data were analyzed using 
model-independent and model-dependent methods. Since diffusion, dissolution and 
erosion effects influence drug release in most cases a simple kinetic model is unlikely 
to explain the overall in vivo release behavior. Thus the in vitro drug release curves 
were analyzed according to the theoretical models of Higuchi and Korsmeyer-Peppas. 
For the formulation with predominant diffusion controlled release level A IVIVC 
could be established (R²= 0.986). Independent on drug release mechanism a level B 
correlation between the mean in vitro dissolution time (MDT) and mean in vivo 
residence time (MRT) was obtained with a correlation coefficient of 0.983. Finally, 
level C correlation were observed when single in vitro parameters, e.g. T50% (time 
required to release 50% of drug in vitro) where compared with single in vivo 
parameters like AUC. This study suggests that a level B correlation could be achieved 
even when drug release occurs by a combination of diffusion and erosion processes. 
More sophisticated in vitro models mimicking drug release under in vivo conditions 
are clearly desirable for parenteral depot formulations. 
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1. Introduction 
In the past decades several parenteral depot formulations based on biodegradable 
polymers such as microspheres and implants have become commercially available to 
improve the efficacy and prolong activity of several peptide and protein drugs [1-3]. 
Poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA) are the most 
frequently used polymers for the preparation of these biodegradable delivery systems 
[4]. It is widely accepted that drug release from biodegradable delivery systems 
occurs by a combined mechanism of drug diffusion and polymer degradation or 
bioerosion [5, 6]. Factors, including polymer molecular weight, copolymer 
composition, crystallinity, and drug loading have a profound effect on drug release 
profiles [7-10]. As a result, drug release frequently does not follow a zero order 
kinetic which is desired from design perspective.  
Different apparatus and methods have been developed to establish in vitro/ in vivo 
correlations (IVIVC) for biodegradable, parenteral dosage forms [11, 12]. However, 
only few examples can be found in literature where an in vitro drug method accurately 
predicts the in vivo release profile for parenteral biodegradable depot systems [13]. 
This demonstrates the difficulties in establishing IVIVC for this class of formulations 
due to the large number of parameters potentially affecting drug release in vivo and in 
vitro.  
To establish IVIVC, at least three batches of the same drug substance should be 
available which differ in their in vivo as well in vitro performance [14, 15]. In 
general, the utilization of in vitro dissolution data for predicting in vivo performance 
requires a reliable method of data transformation. A comparison between in vitro and 
in vivo data is often not possible since the data describing in vivo release/ absorption 
profiles are not directly accessible. Various mathematical models and equations have 
been described in literature for conversion of measurable pharmacokinetic data to 
release/ absorption characteristics of the drug from the delivery systems for 
comparison with the in vitro release data [16, 17]. Depending on the method used to 
correlate the data, the USP established different levels of correlation, designated as A, 
B and C, in decreasing order of preferences and acceptability [15]. Level A IVIVC 
represents a point-to-point correlation between the in vivo absorption profile and the 
in vitro release profile. The in vivo absorption profile is calculated from plasma-
concentration time curves using convolution or deconvolution methods. However, if a 
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level A correlation can not be established attempts should be made to correlate at 
level B. Level B correlations are based on statistical moment analysis and compare 
the mean in vitro dissolution time of the formulation with either the mean residence 
time in the body or the mean in vivo dissolution time of the formulation. Although a 
single parameter is compared in level B IVIVC, the method is known to be useful for 
extended release products.  
Less informative is a level C IVIVC which may be useful for formulation 
development. This type of correlation represents a single point relationship and 
compares e.g. the time required for 50 % drug release in vitro with the area under the 
concentration time curve.  
The intention of this investigation was the analysis of different levels of correlation 
for three different biodegradable implants by using model-dependent (Wagner-
Nelson) and model-independent methods (statistical moment analysis). In order to 
obtain batches that differ in their in vitro performance implants which differ in drug 
loading were prepared by compression molding, then coated at different levels and 
characterized in vitro with respect to their release mechanism.  
In addition, the relationship between release mechanism and quality of IVIVC level 
was assessed. 
2. Materials and methods 
2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA), Type Resomer
®
 RG 502H, lactide/glycolide 
ratio 50:50, molecular weight ( wM ) 17000 Da and poly(L-lactide) (L-PLA), Type 
Resomer
®
 L104, wM  2000 Da were purchased from Boehringer Ingelheim, 
Ingelheim, Germany. Profact Depot 2M
®
,
 
batch C 109, was a gift from Aventis 
(Frankfurt, Germany). The sterile applicator contains two identical rods, each 
containing 3.3 mg buserelin acetate. 
Buserelin acetate, Mw 1350 Da was obtained from Intervet International, 
Unterschleißheim, Germany. All further chemicals and solvents were purchased from 
Merck, Darmstadt, Germany.  
2.2 Preparation of implants 
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The implants were obtained by compression molding of mixtures of polymer powder 
(? 500 µm) and buserelin acetate at various concentrations (10% to 30%). The 
mixtures with drug loadings (DL) of 10, 20 and 30 % w/w were compressed at 15 kN 
using two flat-faced punches of 3 mm in diameter on a single punch press (Korsch EK 
0, Berlin, Germany) at room temperature in manual modus. The implant size was 3 
mm x 1.6 mm and implant weight was approximately 14 mg. Implants for in vivo 
studies were placed in vials sealed under vacuum and gamma-irradiated (19.6 kGy) 
using a 
60
Co source (Rüsch Sterilization Service, Kernen, Germany).  
2.3 Coating of implants 
PLGA implants with a diameter of 3 mm obtained by compression molding were 
coated with L-PLA solution (20 % w/v) in methylene chloride by spray coating 
technique. The process was controlled by increase in weight of the implants after 
evaporation of the solvent. The implants were dried for 24 hours at room temperature 
and the final coating thickness was calculated from mass increase. Implants for in 
vivo studies were sterilized by gamma irradiation as described above. 
2.4 In vitro release study 
The in vitro drug release studies were performed in 14 ml screw capped glass vials. 
The implants were placed into the vials and immersed with 12 ml phosphate puffer 
(0.05 M, pH 7.4) containing 0.05 % benzalkonium chloride and 0.1% sodium azide as 
antibacterial agents. Samples (n=6) were incubated at 37 °C for 4 weeks without 
agitation and were only shaken for 5 s at sampling time. At defined time points 8 ml 
of the release medium were withdrawn and replaced with fresh buffer. The removed 
medium was analyzed for amount of drug released by HPLC.  
The release data were evaluated by model-dependent (curve fitting) and model-
independent methods. For model-dependent analysis two theoretical models 
describing drug release from polymeric systems according to Higuchi [18] and 
Korsmeyer-Peppas were used [19, 20]. Higuchi describes drug release as a diffusion 
process based on Ficks law according to the equation:  
1/2
H tkQ ??             (1) 
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where Q is the amount of drug released in time t and kH is the Higuchi dissolution 
constant. According to this model, a straight line is expected for the plot of Q versus 
the square root of time if drug release from the matrix is based on a diffusion 
mechanism.  
The Korsmeyer-Peppas model takes into account that drug release mechanism often 
deviates from Ficks law and follows an anomalous behavior described by the 
following equation: 
nt tk
M
M ??
?
             (2) 
where Mt is the drug released at time t, M? is the quantity of drug released at infinite 
time, k is the kinetic constant and n is the release exponent. The value of n is related 
to the geometrical shape of the delivery systems and determines the release 
mechanism. For cylindrical devices n is equal to 0.45 for diffusion-controlled release 
whereas n between 0.45 and 1.0 indicates an anomalous non-Fickian transport. Drug 
release from a porous system may lead to n < 0.45 due to the combination of diffusion 
through the matrix and partial diffusion through water-filled pores [20]. For 
evaluation of release data by the described models the portion of the release curve 
where Mt/ M? < 0.6 was used only as described in literature [18]. 
For statistical moment analysis the following model-independent in vitro parameter 
were determined: the mean dissolution time (MDT), percentage of drug released after 
48 h (D48h) and time for 50 % and 63.2 % drug release, respectively (T50%, T63.2%). 
The MDT was calculated according to the equation: 
?
?
M
ABC
MDT
vitroin
            (3) 
where ABC is the area between the release curve and its asymptote, calculated by the 
trapezoidal rule from time zero to the last measured time point, and M? is the total 
amount of dissolved drug at this time point . 
2.5 HPLC analysis 
To determine drug loading and in vitro release, the drug concentrations were obtained 
by direct injection of samples into a HPLC system (Waters 2690, Waters Corporation, 
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Milford, USA). Samples were analyzed for buserelin content using RP-HPLC. 
Separation was performed on a C18 column (225 x 4 mm I.D., Machery Nagel, 
Düren, Germany) at 42 °C. The mobile phase consisted of a mixture of phosphoric 
acid, triethylamine buffer solution pH 2.5 and acetonitrile. The flow rate was 1 ml/ 
min. Detection was performed using a Waters 2470 programmable absorbance 
detector (Waters Corporation, Milford, USA) operating at 216 nm. Calibration curves 
were generated from known concentrations of buserelin acetate in mobile phase. The 
detection limit was 1 µg/ ml. The Millenium 32
®
 chromatography manager, version 
4.0 (Waters Corporation, Milford, USA) was used to analyze the data. 
2.6 In vivo release study 
The pharmacokinetic study reported here was approved by the public board for animal 
experiments. Mature male beagle dogs were used for all studies. They were housed in 
sin a lab dog colony at the Intervet animal farm according to the principles of 
laboratory animal care.  
Dogs with a weight range of 10.6-15.4 kg were randomly divided into 3 groups (n = 
4) and acclimated for at least 4 days prior the studies. Rectal temperature was 
measured before the experiment. Each dog was identified by ear tattoos and received 
one of the three formulations: uncoated implant (batch E), coated implant ( batch F) 
both containing 4.2 mg buserelin or one of two identical rods of Profact depot 2M
®
, 
containing 3.3 mg buserelin (batch G). Using aseptic technique and local anaesthesia 
the implant was administered subcutaneously at the lateral part of the neck on the 
right body side of the dog using an applicator (Cerestar
?
, Intervet NL, Boxmeer).  
At certain time intervals, from 4 hours to 35 days approximately 5 ml of blood 
samples were withdrawn from the Vena jugularis, Vena cephalica antebrachii or Vena 
saphena lateralis and collected in heparinized tubes. The plasma fraction of each 
blood sample was separated immediately by centrifugation and stored at 20 °C in 
labeled heparinized vials until analysis.  
For determination of urinary excretion of buserelin dogs were placed in metabolic 
cages at definite time points for 12 hours. The urine samples were collected in plastic 
tubes and stored at 20 °C until assay. Plasma and urine concentrations of buserelin 
were determined by double-antibody radioimmunoassay [21](Aventis, Frankfurt, 
Germany). 
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2.7 Pharmacokinetic analysis  
Pharmacokinetic parameters for buserelin following subcutaneous (s.c.) application in 
male beagle dogs were determined from the plasma and urine concentration-time data. 
The maximum plasma concentration (Cmax) and the corresponding time (Tmax) were 
obtained directly from the individual plasma concentration-time data. The area of the 
first moment of the concentration-time curves (AUMC) and the area under the 
concentration-time curve from time zero to time t (AUC0-t) were determined by the 
trapezoidal rule. The area from time t to infinity (AUC0-?) was estimated according to 
the equation: 
eltt00 k/CAUCAUC ?? ???  
where Ct is the plasma concentration observed at time t, and kel is the apparent 
elimination rate constant of buserelin obtained from the slope of the linear portion of 
the curve by least square regression analysis [22]. The mean residence time of the 
drug (MRT) and the absolute bioavailability (BV) of the formulations were calculated 
using the following equations: 
AUC
AUMC
MRT ?   
100
dose
dose
AUC
AUC
(%)BV
sc
iv
iv
sc ???  
where AUCsc and AUCiv are the area under the curve after s.c. and i.v. administration, 
respectively. Doseiv and dosesc denotes the amount of drug administered intravenously 
and subcutaneously, respectively. 
Utilizing the i.v. kinetic parameters obtained in a preliminary study [23], the in vivo 
percent of drug absorbed after s.c. administration at each time period was estimated 
by the Wagner-Nelson method [17]. Drug amounts are assessed from rate constants of 
the i.v. two compartment model for each dog and the cumulative area under the curve 
for each dog following s.c. administration of the buserelin implants. Calculations were 
carried out with pharmacokinetic software, Kinetica 2000, version 3.0 (Innaphase, 
Philadelphia, USA). In the compartmental fit the weighting factor was 1/Cp² (Cp is the 
experimental plasma concentration). 
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2.8 Statistical evaluation 
Results are expressed as mean ± SD of four dogs per group. Data analysis of the 
pharmacokinetic parameters was performed by Students t-test. Differences between 
two related parameters were considered statistically significant for p values of or less 
than 0.05.  
2.9 In vitro-in vivo correlation 
Three levels, A, B, and C, of in vitro-in vivo correlation (USP 26) were studied. 
For Level C IVIVC the single release parameters T50%, T63.2%, and D48h were 
compared with the single in vivo parameters AUC0-24h, MRT and Cmax.  
In order to establish Level B IVIVC the mean in vitro dissolution time was compared 
with the mean in vivo residence time. For Level A IVIVC the fraction absorbed in 
vivo, generated by the Wagner-Nelson method, was plotted versus the fraction 
released in vitro at the same time. As alternative method to demonstrate correlation 
the time in vivo for absorption versus the time in vitro for release of the same amount 
of drug was plotted [24]. If there is level A IVIVC, the curves are directly 
superimposable or can be made superimposable by using the time scaling factor and/ 
or the constant offset value [25]: 
vitroinvivoin
tbat ???  
where tin vivo, tin vitro are times in vivo and in vitro, respectively, a is the lag time in vivo 
and b is the time scale factor. The time scale factor takes into account that in vitro 
release and in vivo absorption do not always follow the same time scales. 
3. Results and discussion 
3.1 In vitro release study 
For a drug incorporated in PLGA-based matrices, several possible mechanisms may 
be involved in the release processes: drug diffusion from implants, matrix erosion 
resulting from degradation and dissolution of PLGA polymer and the combination of 
the above two rate processes [26-28]. Furthermore it is known that drug loading and 
drug particle size distribution determine the geometry and the topology of pores and 
channels which determine drug diffusion from the hydrophobic matrix [29]. Drug 
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Figure 1 In vitro drug release from PLGA disc-shaped implants: (a) Influence of drug loading on 
burst effect and (b) Effect of coating on initial release as function of coating thickness. Data are shown 
as an average ± S.D. (n = 6). 
loading affects drug release by changing the porosity of the matrix because channels 
are formed as solid drug is dissolved and released. Such percolation effects in matrix-
type controlled delivery systems were extensively studied by Leuenberger et al. [30, 
31].  
The effect of drug loading on initial drug release of buserelin from PLGA implants is 
shown in Fig. 1a. The drug burst increased significantly with increasing drug loading 
which suggests that buserelin was directly dissolved after contact with buffer and 
diffused into the aqueous medium as expected.  
In order to reduce the drug burst and therewith to retain drug within the matrix 
implants containing 4.2 mg buserelin were coated with low molecular weight L-PLA. 
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The coating had a thickness of 35, 100 or 150 µg/ mm
2
 calculated from mass increase 
(Table 1). The effect of three coating levels on drug release under in vitro conditions 
is shown in Fig. 1b. The initial burst decreased with increasing coating thickness. 
Already at a coating of 35 µg/ mm² a 57 % reduction of the initial release from 2.4 
mg/d to 1.03 mg/d at peak maximum was observed. By increasing the coating 
thickness from 35 to 100 µg/ mm² the reduction of the drug burst was further 
improved by 87 % (from 2.4 mg/d to 0.32 mg/d release). Further coating to a 
thickness of 150 µg/ mm² did not affect drug release any further. However, in contrast 
to results reported in literature [32, 33] a lag-phase of drug release caused by PLA 
coating during the first week was not found.  
This could be explained by the assumption that after spray-coating of implants 
residues of solvent are still in the coating layer resulting in a film of increased 
permeability. The fact that coating and drying was performed below the glass 
transition temperature of the coating polymer contributes to the permeability of film. 
Thus the drug from coated implants is released by diffusion through pores and the 
polymer coating film. The remaining minimal burst effect has a biological component 
and is beneficial because a higher initial release ensures a prompt effect, which can be 
subsequently maintained for a prolonged period by a slower but continuous release of 
buserelin.  
 
Table 1 Kinetic assessment of release data for different buserelin implants 
Higuchi Korsmeyer-Peppas
1
 
Batch 
Drug loading 
(mg) 
Coating 
(µg/mm²) Slope R² slope R² 
A 4.2 0 30.91 0.978 0.343 0.982 
B 4.2 35 26.46 0.990 0.305 0.993 
C 4.2 100 14.28 0.991 0.172 0.990 
D 4.2 150 13.07 0.989 0.228 0.991 
E
*
 4.2 0 31.28 0.996 0.384 0.997 
F
*
 4.2 150 16.75 0.992 0.248 0.999 
G
**
 3.3 0 19.39 0.995 0.233 0.998 
 
1  release exponent n = 0.45 
*  gamma-irradiated with 19.6 kGy 
**  one of the two rods of Profact Depot 2M® 
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In order to determine if the release mechanism of coated implants is governed by 
Fickian diffusion, the results were fitted to both the Higuchi and the Korsemeyer-
Peppas model (n=0.45). According to these models, a straight line is expected foreach 
plot if drug release from the matrix is based on a diffusion mechanism. In both cases 
good correlation coefficients were obtained suggesting that drug release from these 
implants was consistent with a Fickian diffusion mechanism (Table 1).  
For in vivo studies a second set of implants (see Table 1) was prepared, sterilized and 
characterized in vitro. The gamma-irradiation of implants causes a slight decrease in 
polymer molecular weight from 15.9 kDa to 14.3 kDa [34].  
The in vitro drug release of these implants was investigated in a comparative study 
using a commercial available implant (Table 1, batch G). The release profiles are 
shown in Fig. 2. The uncoated implant (batch E) showed a biphasic release pattern, 
with an high initial burst followed by a slower release phase. In contrast, implants of 
identical drug loading coated with 150 µg/mm² L-PLA (batch F) released the drug 
rather constantly. Since the degradation time of coating and matrix polymer was 
similar to the drug release time no lag phase was observed and a daily release of 40 
µg buserelin was achieved over a period of 4 weeks. A longer drug release was 
observed from batch G implants. During the first 2 weeks drug release from these rods 
was faster than from coated implants and more than 69 % of drug was released in 
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Figure 2 In vitro cumulative release profiles for buserelin batches used in the pharmacokinetic 
study up to 35 days. The insert shows the release profile of batch G implants for 70 days. Data are 
shown as an average ± S.D. (n = 4-6). 
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vitro until this time point. However, thereafter drug release rate decreased rapidly and 
only small amounts of drug (~ 10 µg/day) were released constantly over 70 days (Fig. 
2, insert). The result is related to the longer degradation time of polymer where batch 
G implants are based on. The fitting of these data to the Korsmeyer-Peppas model 
demonstrated that drug release within the first 2 weeks occurs mainly by diffusion (n 
= 0.45, R² = 0.998). Thereafter a combination of diffusion and erosion processes 
dominated until the end of the study since the value of n was lower than 0.45 (n = 
0.22, R² = 0.997).  
3.2 In vivo release study 
Based on the in vitro results for developing IVIVC three formulations were selected 
for in vivo evaluation: uncoated implant (E) as the fast-releasing implant, which was 
thought to give the highest initial plasma levels, coated implant (F) which was 
expected to lead to smaller initial plasma levels and thus to a prolonged release phase, 
and Profact Depot 2M
® 
(G) which was thought to give small plasma levels after 2 
weeks as observed in vitro. 
Fig. 3a shows the in vivo plasma buserelin concentration-time profiles after i.v. 
injection of buserelin solution [23]. The rapid decrease in buserelin concentration 
after i.v. administration reflects the fast disposition and elimination of the drug. The 
plasma concentration-time profiles can be described by a two compartment model 
according to the equation: 
Cp= Ae
-? t 
+ Be
-? t
 
where Cp is the plasma concentration of buserelin at time t; A and B are empirical 
constants; and ? and ? are hybrid rate constants.  
The rate constants ? and ? were derived from the slopes of the decline in plasma 
concentration during the initial distribution and the terminal elimination phase. From 
the estimated slopes the half-lifes of ? and ? phase were calculated as t1/2? = 0.693/? 
and t1/2? = 0.693/?.  
The elimination rate constants of ? and ? phase were found to be 0.162 and 0.012  
min
-1
, respectively and the half-lifes of ? and ? phase were calculated as t1/2? = 
0.693/? and t1/2? = 0.693/?. The obtained half-lifes were 4.3 min (?-phase) and 56.4 
min (? phase). The half-life of buserelin obtained from terminal phase is in good  
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Figure 3  In vivo release profiles in dogs: (a) Plot of plasma concentration of buserelin vs. time 
after i.v. administration, (b) Plot of plasma buserelin concentration vs. time and (c) Plot of urine 
buserelin concentration vs. time after s.c. administration of formulation A, B and C. Data are shown as 
an average ± S.D. (n = 3-4). 
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Table 2 Pharmacokinetic parameters following single i.v. administration of 
buserelin (5mg/dog) 
Parameter Mean S.D. 
? (min-1) 0.162 0.032 
? (min-1) 0.012 0.001 
t1/2? (min) 4.3 0.6 
t1/2? (min) 56.4 0.98 
Cl (ml/kg/min) 1.7 0.10 
Vc (ml/kg) 50.1 2.4 
AUC (µg?ml/min) 139.6 12.4 
Vz (ml/kg) 135.9 7.9 
Vss (ml/kg) 118.2 5.5 
MRT (min) 70.7 2.8 
  
 Cl total clearaence 
 Vc volume in the central compartment 
 Vz apparent volume of distribution during the terminal phase 
 Vss apparent volume of distribution at steady state 
agreement with reported values of 25-80 min [35, 36]. The short half-life of buserelin 
explains the rapid decline of plasma concentrations after i.v. administration. The 
pharmacokinetic parameters are summarized in Table 2. 
The mean plasma concentration-time profiles of buserelin after s.c. administration of 
formulations A, B and C are shown in Fig. 3b.  
Since the daily release from tested formulations is low, the plasma concentrations of 
buserelin are very low compared to urine samples where due to the renal excretion 
higher concentrations are reached. Thus urine samples were taken additionally and the 
mean urine profiles of investigated formulations are plotted in Fig. 3c. Table 3 reports 
the mean values of pharmacokinetic parameters obtained when the three studied 
formulations were administered subcutaneously. The results were calculated from 
plasma and urine data by non-compartmental analysis [22].  
After administration of formulation E, containing 4.2 mg drug per implant, high initial 
plasma (Cmax 43.1 ? 5.6 ng/ ml at 4 hrs) and urine levels (Cmax 1018 ? 250 ng/ ml at 
24 hrs) were observed. Thereafter the plasma concentration dropped rather linear 
below 1 ng/ ml. By comparison, formulation F of equivalent dose produced only
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Table 3  Mean (± S.D.) pharmacokinetic parameters following s.c. administration of buserelin in dogs (n = 4) 
*
  obtained from plasma data 
**  obtained from urine data 
a
  maximum plasma/ urine concentration 
b
  time to achieve maximum concentration 
c
  area under the plasma/ urine concentration-time curve from zero time to 24 hours 
d
   area under the plasma/ urine concentration-time curve from zero time to 4 days 
e
  area under the plasma/ urine concentration-time curve from zero time to infinity 
f
   Mean residence time 
g
  bioavailability 
n.d.  not determined 
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Table 4 ANOVA-test for pharmacokinetic parameters determined from plasma 
data of different buserelin implants  
Parameter E vs. F  F vs. G 
Cmax P< 0.05 n.s. 
Tmax P< 0.05 P< 0.05 
MRT P< 0.05 P< 0.05 
AUC0-1 P< 0.01 P< 0.05 
AUC0-4 P< 0.05 n.s. 
AUC0-? n.s. 
 
P< 0.05 
 
n.s. no statistically significant differences 
P-value indicated the comparison of values of each groups obtained by Students t-test 
negligible buserelin plasma and urine levels (< 1 ng/ ml) during the first days 
increasing with time. The peak plasma (Cmax 13.1 ? 3.7 ng/ ml) and urine 
concentration (Cmax 508.7 ? 55 ng/ ml) were smaller than those obtained with 
formulation E. A statistically significant difference was found between formulation E 
and F in both time and magnitude of the generated peak (p < 0.05). No statistical 
difference was found between the two formulations in AUC0-35d, indicating a  
comparable extent of absorption (Table 4). 
Formulation G, containing only 3.3 mg drug, released buserelin rather constantly after 
an initial burst. The peak plasma (Cmax 14.1 ? 8.3 ng/ ml) and urine concentration 
(Cmax 405 ? 103 ng/ ml) were similar to those obtained with formulation F. There 
were no statistically significant differences between the absolute plasma and urine 
concentrations until day 25 (Table 4). Thereafter the mean concentration level of 
formulation G was higher than that obtained from formulation F. The MRT of 
formulation G was significantly longer compared to formulation F (15.6 vs 9.9 days, p 
< 0.05) (Table 4). However, it should be noted that for formulation G the value 
obtained for MRT is underestimated due to the fact that this formulation is based on a 
polymer which degradation time is longer than the duration of the in vivo study (see 
Fig. 2, insert). In order to estimate the amount of drug released from the tested 
formulations the absolute bioavailability (BV) was calculated from the AUC of i.v. 
injection and the administered dose. The absolute bioavailabilities were 84 ± 17 %, 93 
126 
  Chapter 6 
 
± 18 % and 73 ± 14 % for formulations E, F and G. The results indicate that all 
incorporated drug was released completely from formulation E and F whereas in 
formulation G a small amount of drug was still available in the implant at the end of 
the study.  
3.3 In vitro in vivo correlation 
Level C in vitro-in vivo correlation was investigated for T63.2% versus MRT, Cmax in 
vivo versus the percentage of drug released in vitro after 48 hours (D48h) and between 
T50% and AUC0-1d. A good correlation was observed between these parameters and 
correlation coefficients varied from 0.977 to 0.999 (Table 5). No correlation was 
found between T50% and Cmax in vivo.  
Since level C correlation represents a single point comparison and does not reflect the 
complete shape of the plasma level profile this type of correlation is not predictable of 
actual in vivo performance and is generally only useful as reference in formulation 
development or as a product quality control reference procedure. Level B IVIVC was 
investigated for MDT in vitro versus MRT in vivo and a good correlation was 
obtained (R² = 0.98). 
 
Table 5 Correlation coefficients between in vitro dissolution and in vivo 
pharmacokinetic parameters 
In vitro parameter In vivo parameter R² slope intercept 
MDT 
a 
 MRT 
b
 0.983 1.0224 -1.7477 
T63.2% 
c
 MRT 0.9863 0.9318 -1.888 
T50% 
d
 AUC0-24h
e
 0.9993 -2.0299 19.914 
D48h
f
  Cmax
g
  0.9774 0.8354 -8.3737 
 
a Mean dissolution time 
b Mean residence time 
c Time required to dissolve 63.2% of drug 
d Time required to dissolve 50% of drug 
e Area under the serum concentration-time curve from zero time to 48 hrs 
f Percentage of drug dissolved after 48 hrs 
g Maximum serum concentration 
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Figure 4 Plot of percentage of dose absorbed in vivo versus percent released in vitro 
However, a level A IVIVC is considered to be the most informative and is thus 
recommended for regulatory purposes. Therefore, the amounts of drug absorbed after 
s.c. administration of formulation F which was of interest for further development, 
was calculated by the Wagner Nelson method using the linear trapezoidal rule. 
For testing a level A IVIVC two methods were used: (1) the percentage of drug 
absorbed up to time t was plotted versus the amount of drug released in vitro (Fig. 4) 
and (2) the time in vivo for 0-10-20-30-40-50-60-70-80-90 % absorbed was plotted 
versus the time for in vitro release of the same amounts of drug (Levy plot) (Fig. 5).  
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Figure 5 Levy plot obtained from times for 0-90 % buserelin released in vitro and absorbed in 
vivo 
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Visual inspection of the plots suggests a good correlation of the release profiles. 
However, the best correlation coefficient was obtained when using the Levy plot. The 
relationship obtained from the Levy plot indicates that the curves are not 
superimposable due to the different slope  and an intercept different from zero. From 
the intercept the lag time in vivo was estimate to be 4.05 d.  
4. Conclusion 
The release of buserelin from three different biodegradable implants was determined 
in vitro and compared to the pharmacokinetic profile using model-independent and 
model-dependent methods.  
Level A IVIVC (R² = 0.986) was found for batch E implants. Drug release from these 
implants could be described by the Higuchi model over the entire release period of 4 
weeks. For implants where drug release occurs by a combination of diffusion, 
dissolution and erosion processes a level B IVIVC could be established. Due to the 
fact that the development of a suitable release test for biodegradable delivery systems 
is still a major problem alternative approaches for prediction of in vivo performance 
are needed. In this study we could demonstrate that a comparison of MDT in vitro 
versus the MRT in vivo yielded in a level B IVIVC although no sophisticated release 
model such as flow-through cell or dialysis bags were used. Moreover, it could be 
shown that the in vitro parameter T63.2% can be used instead of MDT in order to 
establish this level of correlation. This means that for formulation development or as 
quality control method for clinical samples an in vitro test may be sufficient which 
monitors drug release until this time. By using model-independent methods also a 
good correlation between in vitro and in vivo parameters was obtained.  
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Summary 
This thesis deals with the degradation and release behavior of aliphatic polyesters 
with special respect to the influence of oligomers on the degradation rate and the 
potential use of these biomaterials for the development of veterinary drug delivery 
systems. 
In Chapter 1 the animal health care market is introduced with regard to opportunities 
and challenges of veterinary drug delivery systems. In the second part of this chapter 
biodegradable polymers used for veterinary applications are discussed with emphesis 
on their degradation and release properties. Current applications of biodegradable 
drug delivery systems in the field of reproduction control, growth promotion, 
vaccination and control of ectoparasites are summarized. Furthermore, perspectives 
and current problems in the field of biodegradable drug delivery systems are 
presented. This chapter concludes with the scope, aims and outline of the thesis. 
Chapter 2 describes the synthesis and characterization of D,L-lactic acid oligomers. 
The oligomers were prepared by polycondensation without catalyst providing a series 
of D,L-lactic acid oligomers with narrow molecular weight distribution. The 
oligomers were analyzed using SEC, DSC and 
1
H-NMR to obtain information about 
their physico-chemical properties as function of average chain length. The interest 
was focused on the determination of the critical molecular weight for water solubility 
of oligomers. It was found that the solubility of oligomers depends on both pH and 
average molecular weight. Polydisperse oligomers with nM  smaller than 830 Da are 
soluble in buffer at pH 7.4 whereas oligomers of nM  ? 830 Da are insoluble.  
In addition the hydrolysis kinetic of oligomer degradation and the mechanism of ester 
cleavage was investigated in vitro. The degradation rate was dependent on the pH of 
incubation medium and the lowest degradation rate was found near a pH value of 4.5 
independent on chain length. An Arrhenius plot was constructed for the calculation of 
the activation energy using an accelerated monomer release test. It was found that 
with increasing molecular weight of oligomer the energy of activation increased. 
Furthermore, it could be shown that hydrolysis under basic conditions proceeds by 
random ester cleavage and/ or backbiting whereas chain-end cleavage was observed 
under acidic conditions.  
After successful synthesis and characterization of a homologous series of oligomers 
the effect of these low molecular weight polymers on the degradation process of 
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PLGA was investigated (Chapter 3). Hence, PLGA films containing oligomers of 
different molecular weight in various amounts were prepared by a solvent casting 
technique and the degradation was monitored by SEC, WAXD, DSC and gravimetric 
methods. The results demonstrated that the incorporation of oligomers clearly affects 
the physico-chemical properties of PLGA films. The hydrophilicity increases, 
whereas the glass transition temperature of the film decreases. It was found that the 
initial mass loss and the amount of water absorbed were functions of average 
molecular weight and concentration of oligomers. In contrast to results reported in 
literature an autocatalytic effect due to the increased number of carboxylic end groups 
of oligomers incorporated was not observed. Moreover, for all oligomer-containing 
films an extended lag phase until onset of polymer erosion was found. It could be 
shown that this finding was related to crystallization which occured during 
degradation of all films. However, the degree of crystallization was higher in films 
containing oligomers and was depending on oligomer concentration and oligomer 
molecular weight. These results lead to the assumption that oligomers cause direct or 
indirect crystallization during the degradation process thus reducing the degradation 
rate.  
As discussed in the previous chapters the degradation of PLGA and PLA occurs via 
bulk erosion which leads often to an unfavourable release profile. Therefore in 
Chapter 4 the degradation of PTA was investigated to determine if introduction of 
cleavable ester and ketal bonds in the polymer side chains results in improved 
degradation properties compared to PLGA. After preparation of PTA implants of 
different size by compression molding the degradation was evaluated under in vitro 
conditions in a comparative study using PLGA implants of same size and dimension. 
It was observed that the shape of PTA implants changed during degradation from a 
flat disc to a bloated convex device most probably due to swelling. After a definite 
time interval the implant shell bursts and water soluble degradation products like 
acetone, ethanol and tartaric acid were found in release medium. In parallel a 
remarkable mass loss was detected which was not observed until this time point. 
Possible mechanisms to explain these finding are discussed. It was also found that the 
implant size had a negligible impact on the degradation and erosion of PTA. 
Furthermore, a differentiation between surface and center as known for bulk eroding 
polymers was observed during the degradation of PTA implants. This leads to the 
conclusion that PTA is also a bulk eroding polymer as PLGA.  
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In Chapter 5 the influence of the degradation behavior on drug release from PTA 
implants was investigated in vitro. Effects of drug loading and implant size on release 
profile were studied in more detail. Our hypothesis that drug release will occur in a 
pulsatile manner was confirmed. The release from PTA implants was characterized by 
an initial burst, followed by a lag-phase where no drug was released and subsequentes 
a second burst occured. After the second burst drug was released by zero order kinetic 
until the end of the study. It was found that the extend of second burst correlates with 
drug loading and increases with decreasing drug loading due to the reduced initial 
burst. Various materials were tested to modify the drug release from PTA implants. 
Already small amounts of excipients (10 % w/w) were sufficient either to modify the 
degree of second burst or to prevent the release of drug in a pulsatile manner. Based 
on these results PTA was identified as a promising biomaterial especially for pulsatile 
drug release systems. 
In Chapter 6 the in vivo release properties of buserelin implants were studied in dogs. 
An attempt was made to develop different levels of in vitro-in vivo correlation for 
biodegradable implants. Hence, PLGA implants containing different amounts of the 
GhRh analogon buserelin were prepared by compression molding and coated at 
different levels in order to modify drug release rate. By using model-independent 
methods such as statistical moment analysis and model-dependent methods (curve-
fitting) the in vitro release profiles were compared to the in vivo performance. A level 
A IVIVC could be successfully established if drug release occurs mainly by diffusion 
through water filled pores. In addition it was found that a level B IVIVC could be 
developed if drug release occurs by a combination of diffusions and erosion 
processes. Furthermore several in vitro parameters were determined which correlate 
well with in vivo parameters resulting in level C IVIVC.  
Perspectives 
This thesis demonstrates that for understanding the degradation process of aliphatic 
polyesters intensive research is still required in order to improve the release 
characteristic from biodegradable delivery systems. 
The influence of D,L-lactic acid oligomers on in vitro degradation of bulk eroding 
polymers was assessed in this thesis and although we demonstrated that oligomers 
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play an important role in this process, further research in this area is necessary to 
explain the complex degradation process. 
 
In this thesis different oligomers were incorporated in PLGA films only and no 
autocatalytic effect was observed. It is therefore recommend to study the effect of 
oligomers on the degradation of massive devices such as implants in order to verify if 
autocatalytisis occurs in this case. Furthermore, the degradation of oligomer-
containing poly(lactide-co-glycolide) films of small molecular weight were 
investigated only. Thus the effect of oligomers on the degradation of heigher 
molecular weight polyester devices should be investigated.  
Another interesting approach would be to visualize the contribution and release of 
incorporated oligomers during the degradation process. This requires the coupling of a 
suitable marker at the carboxylic or hydroxylic chain end in such a way that the bond 
will not be cleaved under degradation conditions. 
Due to the fact that the oligomers synthesized in this thesis were only used for 
degradation experiments further research could be focused on the potential of 
oligomers to modulate or to control drug release.  
 
For the tartaric acid based polymer which has be shown its potential for pulsatile drug 
release first of all the polymer has to be synthesized in the desired quality and with 
described characteristics (Mw, Tg, particle size). Thereafter the following 
recommendations could be made. First, in this thesis cylindrical-shaped implants were 
used for in vitro degradation and release studies only. In consequence, both drug 
release and degradation should be evaluated from microspheres and nanospheres. It is 
expected that drug release will no longer occur in a pulsatile manner.  
Another point that deserves attention is to investigate if a solution of PTA formes in 
situ a gel or implant which could be used as delivery system for drugs.  
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Zusammenfassung 
In Hinblick auf die Entwicklung von innovativen pharmazeutischen 
Veterinärprodukten wurde im Rahmen dieser Arbeit der Abbau- und Freisetztungs-
mechanismus von aliphatischen Polyestern experimentell untersucht. Der erste 
Komplex der vorliegenden Arbeit befaßte sich mit dem Einfluß von Oligomeren auf 
das Abbauverhalten von PLA- und PLGA- Polymeren, im zweiten Teil wurden 
Polytartrate charakterisiert und ihr Potential als bioabbaubare Arzneistoffträger 
untersucht.  
 
Die in der Veterinärpharmazie verwendeten klassischen und neuen bioabbaubaren 
Polymere wurde im ersten Kapitel kurz vorgestellt und deren Abbaumechansimus 
erläutert. Aspekte, die bei der Entwicklung von Tierarzneimitteln zu berücksichtigen 
sind, wurden dargelegt und Einblick in den Tiergesundheitsmarkt gewährt. Aktuelle 
Anwendungsgebiete von bioabbaubaren Arzneistoffträgersystemen für die parenterale 
Wirkstoffapplikation am Tier wurden dargestellt. Hierbei lag der Schwerpunkt in den 
Bereichen Reproduktionskontrolle, Wachstumsförderung, Immunisierung und 
Kontrolle von Antiparasitika. Ferner wurden Probleme und mögliche Perspektiven in 
der Anwendung von bioabbaubaren Polymeren zur Applikation von Wirkstoffen im 
Tier aufgezeigt und diskutiert.  
 
Da der Einfluß von Oligomeren auf das Abbauverhalten und den Abbaumechanismus 
von Poly(D,L-laktiden) und Poly(D,L-laktid-co-glykoliden) in der Literatur 
widersprüchlich diskutiert wird, wurde eine Serie von D,L-Laktide Oligomeren 
synthetisiert und charakterisiert (Kapitel 2). Der Zusammenhang zwischen den 
physikalisch-chemischen Eigenschaften und dem durchschnittlichen Molekular-
gewicht der Oligolaktide wurde mit Hilfe von Größenauschlußchromatographie, 
thermoanalytischen Verfahren sowie Kernspinspektroskopie untersucht. Dabei stand 
die Ermittlung des Löslichkeitsverhaltens der Oligomere in Abhängigkeit zu ihrer 
Kettenlänge im Vordergrund. 
Die Ergebnisse zeigten, daß D,L-Laktide Oligomere mit einem Molekulargewicht von 
Mn ? 830 Da sich bei einem pH-Wert von 7.4 in Puffer lösen, jedoch nicht in Wasser 
und sauren Prüfflüssigkeiten. 
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Da die Löslichkeit der Oligomere einen Einfluß auf die Abbaugeschwindigkeit hat, 
wurde in einer mechanistischen Studie die Hydrolysekinetik und der Mechanismus 
der Esterspaltung als Funktion der durchschnittlichen Kettenlänge untersucht. 
Die Experimente zeigten den Zusammenhang zwischen Abbaugeschwindigkeit und 
pH-Wert des Mediums. Unabhängig vom Molekulargewicht der getesteten Oligomere 
wurde im pH Bereich um 4.5 die geringste Hydrolysegeschwindigkeit gemessen.  
Um die Aktivierungsenergie bestimmen zu können, wurde ein Test entwickelt, mit 
welchem die Freisetzung des monomeren Hydrolyseproduktes (Milchsäure) 
untersucht werden konnte. Die Ergebnisse zeigten, daß die Aktivierungsenergie zur 
Spaltung der Esterbindungen mit steigendem Molekulargewicht der Oligomere 
ansteigt. Ferner wurde durch Variation der Hydrolysebedingungen der Mechanismus 
der Esterspaltung mittels 1H-NMR untersucht. Es konnte gezeigt werden, daß unter 
basischen Bedingungen eine statistische Esterspaltung und/ oder Backbiting 
stattfindet, während unter sauren Bedingungen vermehrt eine Kettenendpaltung 
beobachtet wurde.  
 
Um den Einfluß von D,L-Laktide Oligomeren auf die Abbaugeschwindigkeit von 
aliphatischen Polyestern zu untersuchen, wurden Filme aus Poly(D,L-laktide-co-
glykolide) hergestellt. Oligomere unterschiedlichen Molekulargewichtes wurden in 
verschiedenen Konzentrationen in die PLGA Filme eingearbeitet.  
Die physikalisch-chemische Charakterisierung der Filme zeigte, daß durch 
Einarbeitung von Oligomeren die Hydrophilie des Polymerfilmes steigt, während die 
Glasübergangstemperatur des Filmes sinkt. Aus den Abbauuntersuchungen ging 
deutlich hervor, daß sowohl der initiale Gewichtsverlust als auch die aufgenommene 
Wassermenge in Zusammenhang mit dem Molekulargewicht und der eingearbeiteten 
Oligomermenge stehen. Der in der Literatur beschriebene, auf die verhältnissmäßig 
hohe Anzahl an Carboxylendgruppen basierende katalytische Effekt der Oligomere, 
wurde im Fall der PLGA Filme nicht beobachtet. Im Gegenteil, oligomerhaltige Filme 
wiesen eine längere Verzögerungsphase zwischen dem initialen Massenverlust und 
dem Einsetzen der Erosion auf. Die Untersuchung der PLGA Filme mittels 
Weitwinkelröntgenbeugung zeigte, daß sowohl oligomerhaltige als auch 
oligomerfreie Filme im Laufe der Abbauuntersuchungen kristalline Strukturen 
ausbildeten. Da die Kristallinität in oligomerhaltigen Filmen höher war und zu einem 
früheren Zeitpunkt nachgewiesen werden konnte als in oligomerfreien Filmen, ist 
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anzunehmen, daß Oligomere direkt oder indirekt zur Ausbildung kristalliner 
Strukturen beitragen. Die Tatsache, daß kristalline Bereiche langsamer erodieren als 
amorphe Regionen, erklärt die unterschiedlichen Hydrolysegeschwindigkeiten 
innerhalb des Abbauprozesses. Die Ergebnisse weisen darauf hin, daß ein 
autokatalytischer Polymerabbau durch Oligomere eher unwahrscheinlich ist. 
 
Obwohl die Freisetzung von Wirkstoffen aus PLGA Systemen aufgrund der 
Bulkerosion nur selten einer Kinetik nullter Ordnung folgt, ist es das wohl am 
häufigsten verwendete Biomaterial.  
Ein auf Weinsäure basierendes Polymer, welches sowohl spaltbaren Ester- als auch 
Ketalbindungen enthält, ließ verbesserte Abbau- und Freisetzungseigenschaften 
vermuten. Da die Kettenspaltung sowohl in der Haupt- als auch in den Seitenketten 
stattfindet, können schneller wasserlösliche Abbauprodukten gebildet werden. 
Nachdem die Implantate erfolgreich durch Direktverpressung unter hohem Druck 
hergestellt worden waren, wurde eine vergleichende Studie zum Abbauverhalten von 
PTA und PLGA Polymeren durchgeführt (Kapitel 4). Um Rückschlüsse auf den 
Abbaumechanismus von PTA zu erhalten, wurden PTA Implantate mit 
unterschiedlichen Abmessungen hergestellt und erodiert. Bei den gewählten 
Größenverhältnissen zeigten die Abbauprofile keine Veränderung des 
Abbaumechanismus. Das deutet darauf hin, daß PTA Implantate nicht nach dem 
Mechanismus der Oberflächenerosion abgebaut werden, sondern nach dem 
Mechanismus der Bulkerosion. Durch Quantifizierung der Abbauprodukte konnte 
gezeigt werden, daß es in den PTA Implantaten zu einer Aufkonzentrierung von 
Weinsäure, Ethanol und Aceton kommt. Diese werden schlagartig freigesetzt, wenn 
das Implantat platzt und erklären den extremen Massenverlust der Implantate von 
diesem Zeitpunkt an. Die Quellungs- und Massenverlustprofile der PTA Implantate 
unterschieden sich deutlich von denen der PLGA Implantate, deßhalb wurde ein 
neuartiges Freisetzungsprofil erwartet.  
 
Mittels eines Testsystemes wurde die Freisetzung des Modelpeptides Buserelin aus 
PTA Implantaten in vitro untersucht (Kapitel 5). Ein Vorteil des angewendeten 
Herstellverfahrens liegt, im Gegensatz zu bereits bekannten Verarbeitungsmethoden 
(Extrusion, Mikroverkapselung), in der Abwesenheit organischer Lösemittel sowie in 
der fehlenden Temperaturbelastung von Wirk- und Hilfsstoffen. Der Einfluß des 
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Beladungsgrades und der Größe des Implantates auf das Freisetzungsprofil wurde 
untersucht. Unabhängig von diesen Parametern wurde ein pulsatiles 
Freisetzungsverhalten beobachtet. Dieses war durch eine erhöhte Initialfreisetzung, 
gefolgt von einer Phase geringer Wirkstoffabgabe und einer sich anschließenden 
erneuten Phase erhöhter Wirkstofffreisetzung charakterisiert. Es konnte gezeigt 
werden, daß mit steigendem Beladungsgrad und abnehmendem Implantatdurchmesser 
der initialen Burst steigt, während die Wirkstoffmenge, die innerhalb kurzer Zeit 
schlagartig freigesetzt wird, abnimmt. Auf Grund dieses Zusammenhanges kann die 
Dosis, die pulsatil freigesetzt werden soll, angepaßt werden. Durch Variation der 
Implantatzusammensetzung (Zusatz hydrophiler oder lipohiler Substanzen) wurde die 
Möglichkeit zur Steigerung oder Reduktion der Freisetzungsgeschwindigkeit aus PTA 
Implantaten untersucht. Das pulsatile Freisetzungsprofil konnte durch die Zugabe von 
kleinen Hilfsstoffmengen (< 10 %) so geändert werden, daß der Wirkstoff nahezu 
konstant freigesetzt wurde. Die Untersuchungen deuten darauf hin, daß PTA 
Implantate als Träger für Arzneistoffe, die pulsatile freigesetzt werden sollen 
(Hormone, Vaccine), besonders geeignet sind. 
 
Da basierend auf in vitro Freisetzungungen nur selten kinetische Daten vorhergesagt 
werden können, wurde versucht durch Anwendung der statistische Momentanalyse 
bzw. der mathematische Dekonvolution, in vitro Daten mit in vivo Ergebnissen zu 
korrelieren (Kapitel 6). Dafür wurden PLGA Implantate hergestellt, die 
unterschiedliche Wirkstoffmengen enthielten. Das Freisetzungsprofil wurde durch 
Auftragen eines Polymerfilmes modifiziert. Auf Grundlage der in vitro 
Untersuchungen wurden drei PLGA Implantaten unterschiedlicher Zusammensetzung 
ausgesucht und das Freisetzungsverhalten von Buserelin aus diesen Implantaten im 
Hund untersucht. Im Falle des überzogenen Implantates ergab sich eine exzellente 
Übereinstimmung zwischen der Freisetzung in vitro und der Absorption in vivo 
(Level A IVIVC), da der Wirkstoff hauptsächlich durch Porendiffusion freigesetzt 
wurde. Anhand der Untersuchungen konnte gezeigt werden, daß für Implantate deren 
Wirkstofffreisetzung sowohl durch Diffussion als auch durch Abbauvorgänge 
gesteuert wird, die mittlere Auflösezeit in vitro mit der mittleren Verweildauer der 
Substanz im Organismus korreliert (Level B IVIVC). Ferner wurden verschiedene in 
vitro und in vivo Größen ermittelt, für die eine Level C Korrelation erstellt werden 
konnte. 
Appendices 
 
144 
 
  Appendices 
 
145 
Appendices 
 
146 
Curriculum Vitae 
Persönliche Daten 
 
Name:    Gesine Schliecker 
Geburtsdatum /- ort:  16.06.1973, Wernigerode 
Familienstand:   ledig 
Nationalität:   deutsch 
 
 
Schulbildung 
 
1980-1990    Polytechnische Oberschule, Schierke 
1990-1992    Gerhard-Hauptmann Gymnasium, Wernigerode 
Juni 1992    Abitur  
 
 
Berufsausbildung: 
 
1992-1996 Studium der Pharmazie an der Martin-Luther-
Universität, Halle 
März 1995    1. Staatsexamen 
Sept. 1996    2. Staatsexamen 
Sept. 1996 - März 1997 Pharmaziepraktikum in der Moritz-Apotheke, Meissen 
März 1997 - Sept. 1997 Pharmaziepraktikum in der Abt. Qualitätskontrolle 
Hennig Arzneimittel GmbH, Flörsheim 
Okt. 1997    3. Staatsexamen und Approbation als Apotheker 
 
 
Berufstätigkeit und Weiterbildung: 
 
Okt. 1997  Jan. 2000 angestellte Apothekerin, Galenische Entwicklung, 
Hennig-Arzneimittel GmbH, Flörsheim 
Jan. 2000 Wissenschaftliche Mitarbeiterin des Instituts für 
Pharmazeutische Technologie und Biopharmazie der 
Philipps Universität, Marburg 
Anfertigung der Dissertation unter Leitung von Herrn 
Prof. T. Kissel in der Abteilung Product Development 
der Firma Intervet Innovation GmbH, Schwabenheim 
